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JLSstract 
AS2O3 is a major ingredient of arsenic compounds in Traditional Chinese 
Medicine (TCM). Although it is used in the practice of the TCM, its use in cancer 
treatment was discovered till 1970s. The first candidate cancer of AS2O3 treatment is 
acute promyelocytic leukemia (APL). Recently, the anti-tumor effect of AS2O3 was 
expanded to non-APL cancer cells like myeloid leukemia and gastric cancers. 
In the present study, the effect of AS2O3 on human hepatocellular carcinoma 
was studied by in vitro and in vivo experiments. For in vitro study, the cell line, 
HepG2, was used while for in vivo study, nude mice model was used. The present 
study also elucidated the action mechanism of AS2O3. Moreover, the effect of AS2O3 
on multidrug-resistant human hepatocellular carcinoma was studied by the cell line 
R-HepG2, which was characterized with overexpression of P-glycoprotein. 
The result showed that AS2O3 exhibited strong anti-cancer activity. From the 
in vitro study, AS2O3 inhibited the cell proliferation of HepG2 cells in a dose- and 
time-dependent manner. From the in vivo study, AS2O3 exhibited a strong anti-cancer 
effect because it caused a significant reduction (>95%) in both the tumor volume 
(p<0.05) and the tumor weight (p=0.001). Moreover, the results of in vivo study 
showed that AS2O3 at the dosage of 5mg/kg did not damage the liver and the heart as 
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shown by the morphological study as well as measurements of the activity of plasma 
markers of liver and heart injuries, namely alanine transaminase (ALT), aspartate 
transaminase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK). 
The mechanistic study showed that AS2O3 acted through induction of 
apoptosis with activation of caspase-3 but independent of the participation of 
mitochondria. Moreover, AS2O3 did not affect the expressions of glucose transporters 
(Gluts) but it inhibited the glucose uptake and ATP production in a time-dependent 
manner. In addition, AS2O3 significantly reduced the basal glutathione (GSH) level (p 
< 0.01) and increased the activity of glutathione S-transferase (GST) of liver tissue. 
This indicated that reactive oxygen species (ROS) is involved in the action of AS2O3. 
The result also showed that AS2O3 was effective in inhibiting the cell 
proliferation of R-HepG2 cells in a dose- and time-dependent manner and possibly 
acted through induction of apoptosis. This result suggested that AS2O3 is not a 
substrate of P-glycoprotein and may extend the use of AS2O3 in multidrug-resistant 
patients. 
In sum, AS2O3 was found to be an effective anti-cancer drug. However, its 
action mechanism and its potential toxicity toward normal tissues are still not 
completely understood. 











達 P 糖蛋白(P-glycoprotein)� 
硏究結果顯示三氧化二砷有很強的抗癌效能。從試管硏究中，三氧化二砷 
能抑制HepG2細胞生長，其效力爲劑量及作用時間依賴性。另外，動物實驗顯 
示三氧化二砷能有效減低腫瘤體積 ( P < 0 .05)及腫瘤重量 (P = 0 . 0 0 1 ) ’減低幅度 





制葡萄糖的攝取量及A T P的生產。再者，三氧化二砷降低肝組織內的谷胱甘 
(GSH)含量，同時提高谷胱甘轉移（GST)的活性，這表示三氧化二砷的機制 
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Chapter 1 
Introduction 
1.1 Characteristics of Arsenic Compounds 
Arsenic is a common constituent of the earth's crust. It is classified as a 
transition element or metalloid. It can exist in 3 different oxidation or valence states, 
namely, as the metalloid which is of oxidation state 0, arsenite which is of oxidation 
state +3 or known as trivalent, and arsenate which is of oxidation state +5 or known 
as pentavalent (Gorby，1994). Arsenic compounds have been used in a wide variety 
of areas. For instance, they are used in herbicides and insecticides, chromated copper 
arsenate (V) and ammoniacial copper arsenite (III) are used in wood treatment as 
preservatives, sodium arsenate is used to control fungi which cause measles on 
grapes as well as sodium arsenite and monomethylarsonate are used as weedkillers 
(Gorby, 1994, Naqvi, et al., 1994 and Reglinski, 1998). 
1.1.1 Arsenic Compounds are Used as Poisons 
Different arsenic compounds have different degrees of toxicity. Among the 
arsenic compounds, inorganic trivalent compounds can be considered as the most 
I 
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toxic. Organic trivalent compounds rank second. Inorganic and organic pentavalent 
compounds follow. The elemental arsenic is the least toxic (Gorby, 1994 and Morton, 
et al.，1994). In fact, toxicities also depend on other factors like physical state (e.g. 
gas, solution, powder), particle size, the rate of absorption into cells, the rate of 
elimination, the presence of impurities and the pre-existing state of the patients. 
Although arsenic compounds have various usages, people often use them as poisons. 
Among various arsenic compounds, arsenic trioxide (AS2O3) was once considered to 
be the poison of poisons (Gorby, 1994). 
1.1.2 Arsenic Compounds are Used as Medicine 
Although arsenic compounds are toxic, they are explored for the use as 
medicine in both the Western and Chinese societies. In Western medicine, there were 
numerous arsenic-containing drugs like Fowler's solution, Asiatic pills, DeValagin's 
elixir. They were used to treat neuralgia, rheumatism, asthma and hematologic 
abnormalities etc. Among these drugs, Fowler's solution was the most famous and 
widely prescribed. However, it was withdrawn from the market in the 1950s after 
several cases reporting that prolonged use of Fowler's solution induced skin changes, 
cutaneous malignant lesions and neuropathies (Gorby, 1994 and Shen, et al., 1997). 
On the other hand, arsenic compounds are used in the practice of the Traditional 
I 
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Chinese Medicine (TCM) for years, with the principle of 'using a toxic against 
another toxic，(Shen, et al., 1997). Among various arsenic compounds, the medicinal 
effect of AS2O3 was focused in this project. 
1.2 Arsenic Trioxide is a Traditional Chinese Medicine 
AS2O3 is a major ingredient of arsenic compounds in TCM. It is derived from 
Pi'shi (石比石）by sublimation (Fig. 1.1). In the practice of the TCM, AS2O3 is used 
externally to cure hemorrhoids, acute ulcerative gingivitis, asthma and relapsing 
dysenteiy. Moreover, it can eliminate the phlegm and prevent the recurrence of 
malaria (楊倉良，1991,楊芬明，1992，中醫藥發展籌備委員會，1997 and侯士良， 
1999). In addition，arsenous acid or AS2O3 paste can be used to treat tooth marrow 
disease as a devitalizing agent (Shen, et al., 1997). 
In fact, its clinical use on cancer treatment was discovered by a group of 
Chinese doctors in 70s. During the Cultural Revolution, a team of doctors from 
Harbin Medical University was sent to countryside to document Chairman Mao 
Tse-tung's belief in the superiority of TCM over Western practices. They found that 
the secret ingredient in various TCM formulations for the treatment of skin disorders, 
arthritis and other maladies is AS2O3 (Merris, 1996). Since then, AS2O3 is widely 
studied for its ability in treating cancer. 
1 
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Fig. 1.1 Photographs showing Pi'shi and Arsenic Trioxide (AS2O3). (from 中醫藥 
發展籌備委員會,1997) 
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1.3 Properties of Arsenic Trioxide 
AS2O3 is an arsenic compound with oxidation state +3 or known as trivalent. 
In fact AS2O3 is an empirical formula. The real formula should be AS4O6 and the 
structure is shown in Fig 1.2 (Godfrey, et al, 1998). Nevertheless, AS2O3 is a 
common name and is universally recognized. Therefore, the name and the formula of 
arsenic trioxide as AS2O3 were used throughout the thesis. 
AS2O3 can form complexes with metals. It can also react with carbon, 
hydrogen and oxygen to form covalent bonds. Moreover, it has a strong affinity for 
sulphur. Therefore, AS2O3 reacts readily with sulfhydryl-containing compounds 
(Gorby, 1994，Voet, et al., 1995 and Reglinski, 1998). 
i 
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Fig. 1.2 The structure of AS2O3. (from Godfrey, et al., 1998) 
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1.4 Use of Arsenic Trioxide in Cancer Treatment 
1.4.1 Arsenic Trioxide as a Therapeutic Agent in the Treatment of 
Acute Promyelocytic Leukemia 
1.4.1.1 Characteristics of Acute Promyelocytic Leukemia 
The effect of AS2O3 in cancer treatment was discovered by a group of Chinese 
doctors in 1970s. Since then, studies of AS2O3 in the treatment of cancer become 
I 
popular. In fact, leukemia, especially acute promyelocytic leukemia (APL), is the 
first candidate cancer found to be effectively treated by AS2O3. Moreover, it has been 
most widely studied over these years. 
Leukemia is characterized by malignant expansion of a clone of cells 
independent of cell differentiation. Leukemia can be further classified into different 
types according to the functional and morphological varieties of the cells normally 
found in bone marrow and blood (Alvin, et al.，1990). APL is resulted when 
differentiation of cells is blocked at the promyeloid cell stage. Under normal 
condition, the pluriopotent stem cells differentiate into various blood cells such as 
erythrocytes, platelets, B and T lymphocytes, and the ability of differentiation 
decreases as the ceils become mature (Fig. 1.3). In APL, differentiation is blocked at 
the promyeloid cell stage so that the pluriopotent stem cells cannot differentiate into 
neutrophils. Moreover, cell proliferation does not stopped, but enhanced. Thus, 
29 
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giving rise to cancer (King, 1997). 
APL is also characterized by a specific t(15;17) translocation, so that the 
promyelocytic leukemia gene (PML) on chromosome 15 is fused with the retinoic 
acid receptor a gene (RARa) on chromosome 17 to produce a fusion gene, 
PML/RARa gene. As a result, a fusion protein PML/RARa is produced. PML is a 




suppressor activity. RARa belongs to the steroid receptor superfamily and activates I 
transcription in response to all-trans retinoic acid (ATRA). The resulting fusion 
protein, PML/RARa, impairs the functions of both the PML and RARa. It interferes 
promyelocyte differentiation as well as antagonizes the effect of normal RARa 
(Grignani，et al., 1993, Grignani, et aL, 1994，Chen, et al.，1997, King, 1997，and 
Fiann, et al., 1998). Thus, PML/RARa plays a crucial role in leukemogenesis. 
In fact, there are variant translocations in APL. For instance t(ll;15) and 
t(5;17) translocations (Grignani, et al., 1994 and Chen, et al., 1997). Nevertheless, 
they rarely appear in APL and they are not discussed in the present study. 
d 
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Fig. 1.3 Schematic diagram of haemopoiesis. APL occurs when cell differentiation 
is blocked at the promyeloid cell stage, (modified from Alvin, et al., 1990 and 
Hoffbrand, et al., 1994) 
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1.4.1.2 Treatment of Acute Promyelocytic Leukemia with 
All-Trans Retinoic Acid 
Chemotherapy is applied in the treatment of APL. Among various drugs, 
all-trans retinoic acid (ATRA) is more commonly used. ATRA is an analogue of 
vitamin A. It acts through induction of terminal differentiation by downregulation of 




1993，Grignani, et al., 1994, Raelson, et al, 1996 and Chen, et al., 1997). Clinical 
trials also showed that oral administration of 45-lOOmg/mVday of ATRA for 1-2 
months induced complete remission or partial remission in APL patients (Huang, et 
al.，1988). 
However, there are some limitations related to ATRA treatment. The adverse 
side effects of ATRA treatment include dry skin and mucosae, nasal stiffness and 
itching etc. Nevertheless these side effects are generally well-tolerated and can be 
controlled by symptomatic therapy. The more severe side effect is called retinoic acid 
syndrome, which is characterized by fever, respiratory disease, radiographic 
pulmonary infiltrates, renal impairment or even cardiac failure. If it is not treated 
correctly, death may result. The major problem of ATRA treatment is that 30-40% of 
patients relapse within 5 years of complete remission, and the majority of patients 
lost sensitivity to ATRA and other drugs (Huang, et al., 1988, Grignani, et al, 1994 
i 
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and Chen, et al., 1997). In other words, multidrug resistance is developed in cancer 
cells after prolonged treatment of ATRA which poses great barrier in further 
treatment of APL patients with ATRA or even other anti-cancer drugs. In view of this, 
alternative treatment is needed in order to cure APL. 
1.4.1.3 Treatment of Acute Promyelocytic Leukemia with Arsenic 
I I ！ 
j 
Trioxide 
Because of the limitations of ATRA, AS2O3 is used as an alternative 
therapeutic agent in APL. Generally, AS2O3 is considered as poison. Nevertheless it 
can serve as an anti-cancer drug if the concentration of AS2O3 used for medication is 
i j 
well controlled. The lethal dose of AS2O3 for adult individual is 100-200mg 
(Benramdane L., et al., 1999). Thus, the dosage of AS2O3 used in APL patients, 
lOmg/day or plasma concentration of 2)aM, is low when compared with the lethal 
dosage. Both in vitro studies and clinical trials showed that AS2O3 at this dosage is 
effective in treating APL. 
In vitro studies showed that AS2O3 exerted dose-dependent dual effects on 
APL cells. At low concentration, i.e. 0.1-0.5|LIM, AS2O3 induced partial differentiation 
of A P L cells while at a higher concentration, i.e. 1-2|LIM, AS2O3 induced apoptosis 
(Chen, et al, 1997a and Chen, et al., 1997b). 
i 
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Clinical trials also showed that AS2O3 was effective in inducing complete 
remission of APL patients. Studies carried out by Chinese researchers showed that 
infusion of lOmg/day of AS2O3 in APL patients for 28-60 days induced complete 
remission. The clinical complete remission rate was 65-85% and about 30% of 
patients had a survival of over 10 years (Zhang, et al., 1996, Shen, et al., 1997, Niu, 
et al., 1999，Sun, et al, 1999 and 孫鴻德，1992). The result of clinical trials was i i I 
found to be reproducible in Western society. The U.S. researchers at the Memorial j 
i 
I 
Sloan-Kettering Cancer Center found that complete remission was achieved in APL | 
patients after treatment with 0.06-0.2mg/kg/day of AS2O3，for 12-39 days (Soignet, et 
al., 1998 and Camacho, et al., 2000). Other U.S researchers also found that AS2O3 
was capable in achieving complete remission in APL patients via inducing partial 
differentiation of APL cells (Zhong, et al., 2000). 
The most striking effect of AS2O3 was that AS2O3 was also effective in treating 
multidrug-resistant myeloid leukemia cells. In vitro studies showed that AS2O3 
induced apoptosis of multidrug-resistant acute myelocytic leukemia cell, regardless 
of whether they overexpressed Bcl-2, Bcl-xL, P-glycoprotein or multidrug resistance 
protein (MRP) (Perkins, et al., 2000). Clinical trials also showed that AS2O3 was 
effective in inducing complete remission of relapsed APL patients (Shen, et al., 1997, 
Soignet, et al, 1998，Niu, et al., 1999，Camacho, et al, 2000 and Zhang, et al., 2000). 
i 
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This suggested that there was no cross-resistance between ATRA and AS2O3. 
Recently, AS2O3 (Trisenox™) was approved by the Food and Drug 
Administration, Office of Drug Evaluation I, Division of Oncology Drug Products in 
USA as a cancer chemotherapy agent (Bradley., 2000 and Cohen, et al., 2001). This 
indicated the increasing significance of AS2O3 in the treatment of cancer. 




Moreover, the action mechanism of AS2O3 is not well defined. Thus, efforts are 
needed in the investigation of the mechanisms of AS2O3 as well as to explore its use 
on the treatment of other cancers. 
1.4.1.4 Action Mechanisms of Arsenic Trioxide 
AS2O3 mediated its effect via a number of mechanisms. It is reported that 
AS2O3 exerted its effect by modulation of the fusion protein, PML/RARa in APL 
cells. AS2O3 targeted PML and PML/RARa onto nuclear bodies and induced their 
degradation (Chen, et al, 1996，Zhu, et al., 1997 and Shao, et al., 1998). In turn, 
inducing differentiation and triggering apoptosis. This finding was supported by that 
in clinical trials (Zhang, et al, 2000). However, some studies showed that AS2O3 
could mediate its effect in a PML/RARa independent maimer (Wang, et al, 1998). 
This finding suggested that the effect of AS2O3 is not restricted to cancers which 
i 
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expressed PML/RARa. 
Apoptosis was shown to be one of the key pathways for AS2O3 to exert its 
action in APL cells. Therefore, numerous studies were carried out to investigate the 
mechanism of apoptotic pathway in various cancer cells upon treatment with AS2O3. 
Studies showed that caspase-3 was involved in apoptosis induced by AS2O3 in APL 
cells and other cancer cells such as neuroblastoma cells and gastric cancer cells 
I 
I . 
(Akao, et al., 1999, Zhu, et al, 1999, Cai, et al., 2000 and Jiang, et al., 2001). | 
i 1 ! I 
Moreover, AS2O3 caused the collapse of mitochondrial membrane potential in APL 
cells (Kroemer, et al” 1999，Zhu, et al., 1999 and Cai, et al., 2000), which meant 
mitochondria participated in the As203-induced apoptosis. 
Studies also showed that AS2O3-induced apoptosis involved glutathione 
(GSH) redox system in APL cells (Dai, et al” 1999, Jing, et al” 1999，Yang, et al” 
1999 and Bachleitner-Hofmann, et al.，2000). They found that the antioxidant 
capacity affected the sensitivity of these cancer cells toward AS2O3. Cells like APL 
cells and bladder cancer cells with low intracellular GSH level as well as low level of 
antioxidant enzymes like glutathione peroxidase, catalase and glutathione 
S-transferase were more sensitive toward AS2O3. However, the exact mechanism of 
AS2O3 on GSH redox system was not well defined. Jing (1999) suggested that AS2O3 
attacked the vicinal thiol group of glutathione peroxidase, in turn, inhibiting its effect 
i 
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on scavenging free radicals and/or it increased the production of reactive oxygen 
species (ROS). 
In sum, AS2O3 mediated its effect through a number of pathways including 
induction of differentiation by degradation of PML/RARa, induction of apoptosis 
which involved caspase-3 activation and participation of mitochondria, as well as 
involvement of GSH redox system. Nevertheless, the whole picture of the action 
I i 
mechanism of AS2O3 was still remained unclear. : i ！ i 
1.4.2 Arsenic Trioxide as a Therapeutic Agent in the Treatment of 
Non-APL Leukemia 
I 
The cytotoxic effect of AS2O3 was not specific to APL cells. Studies showed 
that AS2O3 was effective in inhibiting the growth of non-APL leukemia cells like 
HL-60 and U937, which were myeloid cells (Wang, et al., 1998 and Iwama, et al, 
2001). In addition, AS2O3 induced apoptosis in malignant lymphocytic cell lines such 
as BJAB cells which were B-cell lymphoma, and SKW-3 cells, which were chronic 
lymphocytic leukemia (Zhu, et al., 1999). This allowed the expansion of the use of 
AS2O3 in the treatment of leukemia of non-APL type. 
i 
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1.4.3 Arsenic Trioxide as a Therapeutic Agent in the Treatment of 
Solid Tumors 
The use of AS2O3 in cancer treatment was further explored to solid cancers. It 
was reported that the therapeutic concentration of AS2O3 (0.5-2|iM) inhibited the 
growth of gastric cancers (Zhang, et al., 1999 and Jiang, 2001), neuroblastoma (Akao, 
et al., 1999 and Ora, et al., 2000), esophageal carcinoma (Shen, et al., 2000) as well 
i ( 
as head and neck cancers (Seol, et al., 1999). Moreover, AS2O3 was shown to be 
effective in the treatment through induction of apoptosis or cell cycle arrest. In my 
project, I explored the effect of AS2O3 on human hepatocellular carcinoma. | 
1 • 5 Human Hepatocellular Carcinoma 
1.5.1 The Incidence of Liver Cancer 
Malignant neoplasm is the number 1 killer in Hong Kong. Among various 
cancers, liver cancer is the second commonest. In fact, the incidence rate of liver 
cancer in the world is not low. It can be considered as the commonest cancer in the 
world with an annual incidence of 1,000,000 cases (http://www.ha.org.hk). Thus, 
there is a need to improve the current treatment as well as to explore new methods to 
treat liver cancer. 
i 
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1.5.2 Classification of Liver Cancer 
Liver cancer can be classified into 2 types according to the histology. They 
are hepatoblastoma and hepatocellular carcinoma. Hepatoblastoma is mostly resulted 
from genetic abnormalities while hepatocellular carcinoma is usually associated with 
hepatitis B and C infection. Moreover, hepatoblastoma is most often unifocal, while 
hepatocellular carcinoma is often extensively invasive or multicentric. Therefore, 
i 
resection is possible more often in hepatoblastoma than hepatocellular carcinoma 
rhttp://www.upci.upmc.edu). In other words, it is more difficult in treating 
hepatocellular carcinoma than hepatoblastoma. In addition, the incidence of 
hepatocellular carcinoma is higher in the Chinese society because of higher incidence 
of hepatitis B or C in Asian countries including Hong Kong and the Mainland. Thus, 
new remedy for hepatocellular carcinoma is in an urgent need. 
In view of this, hepatocellular carcinoma was the target of my project. 
1.6 Aim of the Project 
In my project, studying the effect of AS2O3 on human hepatocellular 
carcinoma was my main concern. The effect of AS2O3 was investigated by in vitro 
and in vivo experiments. For the in vitro study, human hepatocellular carcinoma cell 
line, HepG2, was used. The anti-proliferative effect as well as the action mechanism 
• 
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of AS2O3 were examined. For the in vivo study, nude mice model was used. Nude 
mice were knockout mice in which the immune system was impaired. Thus, any 
effect on the human tumor inoculated to the mice was due to the drug, but not the 
inborn immune response of the mice. 
Before any investigation of the effect of AS2O3 on human hepatocellular 
carcinoma, comparison between my preparation of drug with others was carried out, 
so that my result can be compared with others. Some researchers used the drug which 
i 
j 
was provided by the hospital and was already applied in the clinical trials (Chen, et I 
al., 1996, Chen, et al., 1997 and Jiang, et al., 2000). Some prepared it themselves. 
i 
However, there was no standardized method in preparing the stock of AS2O3 solution. 
Some simply used water (Lew, et al., 1999) while some used NaOH (Gianni, et al., 
1998 and Perkins, et al., 2000). Nevertheless, most researchers used PBS to prepare 
the drug. In view of this, I used PBS to prepare the AS2O3 stock as that it can be 
further diluted in media or saline and used in in vitro studies and in vivo studies, 
respectively. 
To compare the effect of my preparation of drug with others, the effect of 
AS2O3 on the cell proliferation of NB-4 cells as well as brief investigation of the 
action mechanism of AS2O3 on NB-4 cells were carried out. This was because NB-4 
cell is a typical example of APL cell and is widely used for the study of the effect of 
A 
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AS2O3. Thus, comparison can be made between my result and others as the targeted 
cell type was the same. 
1.6.1 In Vitro Study of the Effect of Arsenic Trioxide on HepG2 
Cells 





cells was examined by MTT assay first. Then the action mechanism of AS2O3 was j 
investigated. The concentration of AS2O3 used in the mechanistic study was fixed to 
2)jM，which was a clinically achievable concentration. Trypan blue exclusion assay 
i was carried out to confirm the effect of AS2O3 at this clinically achievable 
i 
i j 
concentration, i.e. 2jaM，on HepG2 cells. | 
I 
Mechanistic study was then followed. Since previous studies suggested that 
AS2O3 mediates its effect via induction of apoptosis or cell cycle arrest, analysis of 
cell cycle phase distribution after treatment was performed by flow cytometry with 
PI staining. To further confirm whether apoptosis took place upon AS2O3 treatment, 
DNA fragmentation assay and flow cytometry with Annexin V-PI staining were 
carried out. In addition, involvement of caspase cascade and participation of 
mitochondria were examined by Western analysis of caspase-3, and detection of the 
change of mitochondrial membrane potential as well as the release of cytochrome c 
A 
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to the cytosol, respectively. 
Apart from the induction of apoptosis, other action mechanisms may be 
involved. I focused on the effect of AS2O3 on glucose metabolism. The growth of 
cancer cells is much faster than that of the normal cells. The faster proliferation rate 
is accompanied by the increased energy utilization. Since energy mainly derives from 
glucose, much more glucose is required for the development of tumor (Chan, et al., 
i 
1983). The increased glucose uptake is mediated by overexpression of glucose 
transporters (Gluts) (Yamamto, et al., 1990, Younes, et al, 1996 and Au, et al., 1997). 
Therefore, interference of Gluts expression, glucose uptake and/or glucose 
！ 
metabolism of cancer cells may affect the growth of tumors. In view of this, I | i 
investigated the effect of AS2O3 on glucose metabolism by examining the expression 
of Glut 1, which is house-keeping, and Glut 2, which is liver-specific, by Western 
analysis, glucose uptake by glucose uptake assay as well as ATP production by a 
Sigma kit. 
1.6.2 In Vivo Study of the Effect of AszOaby Tumor-Bearing Nude 
Mice Model 
The effect of AS2O3 was further studied by in vivo experiments using 
tumor-bearing nude mice model. HepG2 cells were inoculated to the mice and then 
A 
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AS2O3 was injected to the mice intravenously. The anti-tumor effect of AS2O3 was 
examined by monitoring the tumor size and the tumor volume after the whole course 
of treatment. 
From the clinical trials of AS2O3 on APL patients, side effects were often 
observed. The side effects included dry skin, impaired liver function and 
abnormalities in electrocardiography (Shen, et al., 1997, Soignet, et al., 1998, Sun, et 
al., 1999，Ohnishi, et al., 2000 and Unnikrishnan, et al., 2001). Nevertheless, these 
side effects were well tolerated and/or disappeared rapidly with symptomatic 
treatment. In the present project, the cytotoxic effect of AS2O3 toward normal tissue 
was evaluated by morphological study as well as measurement of the activities of 
plasma enzymatic markers of tissue injuries. 
Since several studies suggested that GSH redox system was involved upon 
AS2O3 treatment (Dai, et al, 1999，Jing, et al., 1999, Yang, et al., 1999 and 
Bachleitner-Hofmann, et al., 2000), the role of GSH redox system in the action of 
AS2O3 was studied by measuring the basal GSH level and the activity of glutathione 
S-transferase (GST) of the liver tissue of the nude mice after treatment with AS2O3. 
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1.6.3 In Vitro Study of the Effect of AS2O3 on Multidrug-Resistant 
Human Hepatocellular Carcinoma Cell Line，R-HepG2 
Multidrug resistant cancer cells may be developed in parental cancer cells 
upon prolonged treatment with anticancer drugs. These cancer cells resist to drugs 
differing in chemical structures as well as mechanisms of action on the cells. Among 
various multidrug mechanisms, overexpression of multidrug transporters, especially , 
I i [ 
P-glycoprotein, is the commonest (Stavrovskaya, 2000). The appearance of 
. - i 
multidrug resistance poses great barrier in the chemotherapy of cancer. As a result, 
] 
numerous methods are developed to improve or reverse the multidrug resistance (Di 
Pietro, et al.，1999, Ueda, et al., 1999 and Chan, et al.，2000). In fact, the arising 
awareness of the use of AS2O3 was due to the inhibitory effect of AS2O3 on 
ATRA-resistant APL cells and on relapsed APL patients. Thus, if AS2O3 is effective | 
；] I 
in treating other multidrug-resistant cancer cells like those overexpressing 
P-glycoprotein, this will add value to AS2O3 to serve as an anticancer drug. In view of 
this, AS2O3 was tested for its ability in treating multidrug resistant hepatocellular 
carcinoma. 
In the study of the effect of AS2O3 on multidrug-resistant hepatocellular 
carcinoma, R-HepG2 cells were used. This cell line is developed by our group as 
described in the Materials and Methods. R-HepG2 cells are characterized with 
A 
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overexpression of mdrl gene as well as P-glycoprotein (Chan, et al., 2000). The 
effect of AS2O3 on cell proliferation of R-HepG2 cells was examined by MTT assay 
and the mechanism of AS2O3 was briefly studied by cell cycle phase distribution 
analysis, DNA fragmentation assay as well as flow cytometry with Annexin V-PI 
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Cfiapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Cell Lines and Culture medium 
I 
i 
2.1.1.1 Cell Lines I 
I 
I Human acute promyelocytic leukemia cell line, NB-4, was obtained from : 
1 i German Collection of Microorganism and Cell Cultures, Department of Human and 
i j 
I Animal Cell Cultures. Human hepatocellular carcinoma cell line, HepG2, was [ i i [ 
purchased from American Type Culture Collection. NB-4 and HepG2 cells were | 
cultured in RPMI-1640 medium (Gibco BRL, USA) with 20% and 10% (v/v) fetal | 
i i 1 ] 
I 
bovine serum (Gibco BRL, USA), respectively. One percent antibiotics (v/v), 
penicillin/streptomycin (10,000units/ml) (Gibco BRL, USA), was added to the 
medium. The cells were maintained at 37°C in a humidified atmosphere of 5% 
carbon dioxide/95% air. 
Multidrug resistant human hepatocellular carcinoma cell line, R-HepG2, was 
developed by our group. To develop R-HepG2 cells, doxorubicin (Sigma Chemical 
Company) was added to HepG2 cells at a stepwise increasing concentration. The 
A 
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resistant cells were selected by removing the dead non-resistant cells. Multiple 
resistance was tested by treating the cells (HepG2 and R-HepG2) with different 
concentrations of anti-tumor drugs (doxorubicin, vicristine and methotrexate) for 48 
hours and MTT assay was performed to determine the percentage survival of cells at 
each concentration. Upregulation of mdrl gene expression and overexpression of 
P-glycoprotein were confirmed by Northern analysis and Western analysis, ^ 
respectively (Chan, et al., 2000). The resistant cells were cultured in RPMI-1640 
i 
medium with 10% (v/v) fetal bovine serum and L2jLiM doxorubicin. The cells were 
j i 
maintained at 37°C in a humidified atmosphere of 5% carbon dioxide/95% air. i j 
I 
i 
2.1.1.2 Culture medium 
RPMI-1640 medium was used for cell culture. Each pack of the powder 
i 
RPMI-1640 containing phenol red, L-glutamine and 0.5mM HEPES was dissolved in 
900ml of distilled water. Two grams of sodium bicarbonate was added. The pH was 
adjusted to 7.2. Distilled water was then added to bring the solution to a volume of 
IL. The complete medium was then sterilized by filtration using a 0.22 |im bottle-top 
filter (Millipore). One milliliter of filtered medium was incubated at 2>TC in a 
humidified atmosphere of 5% carbon dioxide/95% air for 24 hours to test the 
sterilization. The sterilized medium was stored at 4°C. Fetal bovine serum was 
A 
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aliquoted in 50ml volume and penicillin/streptomycin was aliquoted in 5ml volume 
and stored at -20�C. 
2.1.2 Chemicals 
Arsenic trioxide (AS2O3) was purchased from Sigma Chemical Company. 




was dissolved in boiled PBS with stirring. Then it was sterilized by 0.22|Lim filter 
(Milipore) and kept at 4°C. For in vitro studies, different working concentrations of 
AS2O3 were made by diluting the stock with medium. | 
Doxorubicin and vincristine were brought from Sigma Chemical Company. 
They were first dissolved in distilled water. Then they were diluted with PBS to 1 
make a stock of ImM stock and were stored at 4°C. Carbonyl cyanide 
p-(trifluoromethoxy)phenylhydrazone (FCCP) was brought from Sigma Chemical 
Company. It was dissolved in absolute ethanol to give a lOmM stock and stored at 
4°C. Trypan blue and Canada Balsam was brought from Sigma Chemical Company 
while Harris, hematoxylin was purchased from Surgipath. 
A 
Chapter 1 p. 18 
2.1.3 Reagents and Buffers 
2.1.3.1 Phosphate Buffered Saline (PBS) 
PBS was prepared by mixing 136mM NaCl, 2.7mM KH2PO4 and SmM 
NaiPCU in distilled water. The pH was adjusted to 7.4. It was then sterilized by 





2.1.3.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium | 
bromide (MTT) Solution 
1 
I 
MTT powder (Sigma Chemical Company) was dissolved in PBS at a 
1 concentration of 5mg/ml. The solution was filtered by a 0.22|Lim filter (Millipore). 
2.1.3.3 Reagents for D N A Fragmentation Assay | 
I 
2.1.3.3.1 D N A Lysis Buffer 
DNA lysis buffer was prepared by mixing 200mM Tris-HCl (pH8.3), lOOmM 
EDTA and 1% SDS in distilled water. 
2.1.3.3.2 Tris-EDTA (TE) Buffer 
TE buffer was prepared by mixing lOmM Tris-Cl (pH 8.0) and ImM EDTA 
in distilled water. 
A 
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2.1.3.3.3 Tris-Acetate (TAE) Buffer 
TAE buffer was first prepared as a 5 OX concentrated stock solution. It 
contained 242g of Tris base, 57.1ml of glacial acetic acid and 100ml of 0.5M EDTA 
(pH8.0) in IL of distilled water. 
2.1.3.3.4 Proteinase K and Ribonuclease A (RNase A) 
j 
Proteinase K (14 units/mg solid) (Sigma Chemical Company) was dissolved | 
I 
in distilled water in a concentration of lOmg/ml while RNase A (59 Kunitz units/mg | 
I i 1 








6X DNA loading dye was prepared by mixing 0.25% bromophenol blue, 
0.25% xylene cyanol FF and 30% glycerol in distilled water. 
2.1.3.3.6 One Hundred Base-Pair D N A Marker 
One microliter of 1 |Lig/|al of the 100 base-pair DNA marker (Amersham 
Pharmacia Biotech Inc.) was mixed with 5jLil of autoclaved distilled water and 4|al of 
6X DNA loading dye. 
A 
Chapter 2 p.29 
2.1.3.4 Reagents for Western Analysis 
2.1.3A.1 SDS Lysis Buffer 
Lysis buffer was prepared by mixing ll^ig/ml aprotinin, 0.5|Lig/ml leupeptin, 
4.9mM MgCli, ImM sodium meta-vanadate, 1% triton X-100 and ImM 
phenylmethylsulfonylfluoride (PMSF) in PBS. It was stored at room temperature. 
I 
2.1.3.4.2 4X Lower Gel Buffer 
4X lower gel buffer was prepared by dissolving 90.8g of Tris base and 2g of 
SDS in 400ml of distilled water. The pH was adjusted to 8.8 with HCl. Then, 
distilled water was added to bring the solution to a volume of 500ml. 
2.L3.4.3 4X Upper Gel Buffer 
Y 
I 
4X upper gel buffer was prepared by dissolving 30.3g of Tris base and 2g of 
SDS in 400ml of distilled water. The pH was adjusted to 6.8 with HCl. Then, 
distilled water was added to bring the solution to a volume of 500ml. 
2.1.3.4.4 lOX SDS Running Buffer 
lOX SDS running buffer was prepared by dissolving 30.3g of Tris base, 144g 
of glycine and lOg of SDS in IL of distilled water. The concentrated stock solution 
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was diluted 10-fold to give the working concentration. 
2.1.3.4.5 2X SDS Sample Loading Dye 
2X SDS sample loading dye was prepared by mixing 1.5 Ig of Tris base, 20g 
of glycerol, 4.6g of SDS, 10ml of 2-mercaptoethanol and 80ml of distilled water. The 
pH was adjusted to 6.8 with HQ. Then, distilled water was added to bring the , 




2.1.3.4.6 Electrobloting Buffer 
Electrobloting buffer was prepared by mixing 66.7ml of lOX Tris-glycine 
(30.3g of Tris base and 144g of glycine in IL of distilled water) (pH8.3), 100ml of 
methanol and 500ml of distilled water. 
2.1.3.4.7 Tris-Buffered Saline with 0.1% Tween-20 (TBS-T) 
lOX TBS stock was prepared by dissolving 12.114g of Tris and 87.66g of 
NaCl in IL of distilled water. The pH was adjusted to 8. The stock solution was then 
diluted 10 fold to give the IX working concentration. For IL of IX TBS, 1ml of 
Tween-20 was added. 
A 
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2.1.3.4.8 Lysis Buffer for Detection of the Release of 
Cytochrome C 
A special lysis buffer was prepared for detection of the release of cytochrome 
c from the mitochondria. The formulation of the lysis buffer was according to Single 
et al. (1998). The lysis buffer was prepared by mixing 75mM NaCl, ImM NaHiPCU， 




PMSF and 0.5|Lig/jLil digitonin and it was prepared freshly. j i. 
i 1 i 
2.1.3.5 Propidium Iodide (PI) 
PI solution was prepared by dissolving 2mg of PI in 1 ml of PBS and stored 
at 4°C. ； I ) 
I t 
2.1.3.6 5,5,，6,6，-tetrachloro-l，1，，3,3,-tetraethylbenzimidazolyl-
carbocyanine Iodide (JC-1) 
JC-1 was brought from Molecular Probes. It was dissolved in dimethyl 
sulfoxide (DMSO) (Riedel-de Haen) to give a stock concentration of lOmM and 
stored at 4°C. It was diluted to the working concentration of 2.5mM before 
experiment. 
A 
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2.1.3.7 Reagents iotin Vivo Study 
2.1.3.7.1 Saline 
Saline was prepared by dissolving 0.9% NaCl (w/v) in distilled water. 
2.1.3.7.2 Homogenizing Buffer 




in distilled water. The pH was adjusted to 7.6 and stored at 
j i i 
i 
2.1.3.7.3 10% Buffered Formalin 
I 
！ Ten percent buffered formalin was prepared by mixing 100ml of 37% 
j formalin (Sigma Chemical Company) and 900ml of distilled water with addition of j 
• I 
8.5g ofNaCl, 4g ofNaH2P04.2H20 and 6.5g ofNasHPCV j 
2.1.3.7.4 Acid Alcohol 
One percent acid alcohol was prepared by mixing 1ml of concentrated HCl 
with 99ml of 70% ethanol. 
2.1.3.7.5 Scott,s Tap Water 
Scott's tap water was prepared by dissolving 2g of K2CO3 and 20g of MgS04 
i 
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in IL of distilled water. 
2.1.3.7.6 0.5% Aqueous Eosin 
0.5% aqueous Eosin was prepared by dissolving Ig of Eosin Y in 200ml of 
distilled water. Two to three drops of glacial acetic acid were added. 
t 
i j 
2.2 Methods i i ! 




I MTT assay was used to assess the effect of AS2O3 on inhibition of cell j 
1 
i 
I proliferation. For 1-day treatment, 1 x l i / cells/ well were seeded in 96-well plate. } 
For 3-, 5- and 7-day treatments, 5 x lO"^  cells/ well, 3 x cells/ well and 1.5 x lO"^  ；, 




the cells. The medium was changed everyday with drug replaced. After treatment, the 
medium in each well was discarded and washed by PBS. Thirty microliter of MTT 
solution (5mg/ml) was added. The plate was incubated at ZTC for 2 hours. Then, the 
M T T solution was discarded and 100|LI1 of D M S O was added to dissolve the crystals. 
The plate was allowed to stand for 30 minutes at room temperature. The absorbance 
at 540nm was read by ELISA plate reader (BIO-RAD). Blank was set by adding 
lOOjul of DMSO only. Negative control without any drug was set as 100% of cell 
A 
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survival. 
2.2.2 Trypan Blue Exclusion Assay 
Ten microliter of cell suspension was mixed with equal volume of 0.4% 
trypan blue solution (Sigma Chemical Company). The mixture was then transferred 
to the hemocytometer. Only viable cells (unstained cells) were counted. Each square 
of the hemocytometer represented a total volume of O.lmm^. Since Icm^ was 







4 i Cells per ml = average count per square x dilution factor x 10 j 
% control = viable treated cells x 100% 
viable control cells 
% viability = viable treated cells x 100% 
total treated cells 
2.2.3 Analysis of Cell-Cycle Phase Distribution by Flow 
Cytometry with PI Staining 
Cells were seeded in 60mm culture dish. Two micromolar of AS2O3 was 
A 
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added to the cells and incubated with various time. The medium was changed 
everyday with drug replaced. After treatment, cells were harvested and washed twice 
with PBS. Cells at 1 x 10^  were used for cell cycle analysis. The cells were fixed 
with ice-cold 70% ethanol for at least 24 hours at 4°C. Then the cells were 
centrifuged at 300 x g for 5 minutes and the cell pellet was resuspended in 400)al of 
PBS, 50|LI1 of RNase A (lOmg/ml) and 10)il of PI (2mg/ml). The mixture was , 
I I j 
incubated in the dark at 2>TC for 30 minutes and was then analyzed by FACsort flow 
cytometer (Becton Dickinson). 'Cell Quest' program was used. The cell population 
！ 
was scanned by forward scatter (FSC) light and side scatter (SSC) light which i i j reflected the size and the granularity of cells, respectively. Different phases of the 
I 
cell cycle were assessed by collecting the signal at channel FL2-A. The percentage of i 
'i 
i 
cell population at a particular phase was estimated by ModFit LT for Mac V.3.0. 
2.2.4 D N A Fragmentation Assay 
DNA fragmentation assay was used to examine apoptosis. Cells were seeded 
in 60mm culture dish. Two micromolar of AS2O3 was added to the cells and 
incubated with various time. The medium was changed everyday with drug replaced. 
After treatment, cells were harvested and washed twice with PBS. Cells at 1 x 10^  
were lysed with 400|LI1 of DNA lysis buffer. The mixture was vortexed until no cell 
i 
Chapter 2 p.30 
debris was left. Twenty microliter of proteinase K (lOmg/ml) was added and 
incubated at 37®C for at least 2 hours. Then 150|al of saturated NaCl was added and 
the sample was shake vigorously. The microcentrifuge tubes were centrifuged at 
6 5 0 0 X g for 15 minutes. The supernatant was collected and 1ml of cold absolute 
ethanol was added. Another centrifugation at 15000 x g for 20 minutes was applied. 
After rinsed with cold 75% ethanol, it was allowed to diy. Finally, 20 of RNase A , 
j 
(0.2mg/ml) was added to each sample and further incubated at 2>TC for 90 minutes. j 
r 
i 1 
Equal amount of sample was loaded to 1.5% agarose gel (w/v) with ethidium ！ 
bromide (Sigma Chemical Company) and electrophoresis at 80V was applied for 1 
hour and 10 minutes. 
I 
2,2.5 Quantification of Apoptosis by Flow Cytometry with | 
( 
I 
Annexin V-PI Staining 
TAGS™ Annexin V-FITC kit was brought from Trevigen Inc. Cells were 
seeded in 60mm culture dish. Two micromolar of AS2O3 was added to the cells and 
incubated with various time. The medium was changed everyday with drug replaced. 
After treatment, cells were harvested and washed twice with PBS. Cells at 1 x 10^  
were used for the assay. One hundred microliter of Annexin V incubation reagent 
(10|j-l of lOX binding buffer, lOjil of PI, 2jLil of Annexin-V conjugate and 78)al of 
A 
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distilled water) was added and the sample was incubated in the dark at 37°C for 15 
minutes. Four hundred microliter of IX binding buffer was added to the sample and 
the sample was then analyzed by flow cytometry. ‘Cell Quest' program was used. 
The cell population was scanned by forward scatter (FSC) light and side scatter (SSC) 
light which reflected the size and the granularity of cells, respectively. The signal 
was detected by FLl and FL3 channels. , 
I 
I 
2.2,6 Assessment of the Change in Mitochondrial Membrane 
Potential (Aqv) 
The mitochondrial membrane potential (Acpm) was assessed by flow 
cytometry with JC-1. Cells were seeded in 60mm culture dish. Two micromolar of ； 
AS2O3 was added to the cells and incubated with various time. The medium was 
[ I 
changed everyday with drug replaced. After treatment, cells were harvested and 
washed twice with PBS. Cells at 0.25 x 10^  were resuspended in 500|il of medium. 
Two microliter of JC-1 (2.5mM) was added. The sample was incubated in the dark at 
37°C for 15 minutes and then it was analyzed by flow cytometry. Positive control 
was made by adding 2.5\i\ of FCCP (lOmM), which caused the relapse of 
mitochondrial membrane potential, before adding JC-1 and incubated at 37°C for 5 
minutes. ‘Cell Quest' program was used. The cell population was scanned by forward 
i 
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scatter (FSC) light and side scatter (SSC) light which reflected the size and the 
granularity of cells, respectively. The signal was detected by FLl and FL3 channels. 
2.2.7 Western Analysis 
Cells were seeded in 60mm culture dish. Two micromolar of AS2O3 was 
added to the cells and incubated with various time. The medium was changed � 
\ 
everyday with drug replaced. After treatment, cells were harvested and washed twice } 
i 
！ 





allowed to stand on ice for 30 minutes. The sample was then boiled for 10 minutes 
t ；I 
. ! 
and was stored at -20�C. Protein concentration was determined by bicinchonic acid 
(BCA) (Sigma Chemical Company) protein assay. j 
\ I 1 
For detection of cytochrome c，4 x 10 cells were lyzed by 50|LI1 of the special i 
！ 
I 
lysis buffer and incubated for about 30 seconds. The sample was centrifUged at 9,800 
X g for 60 seconds. The supernatant was collected and equal amount of SDS loading 
dye (about 50jLil) was added. The sample was boiled for 10 minutes and then 
centrifuged at 13,600 x g for 7 minutes at 4°C. The supernatant was collected and 
kept for Western analysis. 
The protein minigel apparatus (Hoefer) vertical electrophoresis system with 
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！ i 
of 4X upper gel buffer, 30|al of 10% (w/v) ammonium persulfate (APS) and 5.3)il of 
N，N,N,，N,-tetramethylethylenediamine (TEMED)) and 8% running gel (3.815ml of 
distilled water, 2.135ml of 30% acrylamide, 2ml of 4X lower gel buffer, 40)li1 of APS 
and 9.3|il of TEMED) or 18% running gel (4.8ml of distilled water, 1.15ml of 30% 
acrylamide, 2ml of 4X lower gel buffer, 40|al of APS and 9.3|al of TEMED) running 
gel was used. Equal amount of protein (25-50}ig) was loaded to the gel, while for , 
I I 
cytochrome c，20|al of sample was used. Sodium sulfate-polyacrylamide gel | 
I i 
electrophoresis (SDS-PAGE) was performed with constant voltage 200V. The : 
proteins were then transferred to a polyvinylidene fluoride (PVDF) micorporous 
j 
j 
membrane by semi-dry transfer system (BioRad). The non-specific space of the ( 
membrane was blocked by 10% non-fat milk in TBS-T and stored at 4°C overnight. i 
I' I j； ：丨 
I* Before probing with antibody, the membrane was washed with TBS-T for 15 ； 
» 
minutes for 3 times. Monoclonal antibodies against caspase 3 (1: 400)，cytochrome c 
(1:400), Glucose transporter 1 (1:400), glucose transporter 2 (1:400) or 
P-glycoprotein (1:1000) (Santa Cruz) was added and incubated for 1 hour with 
constant shaking. After probing, the membrane was washed with TBS-T for 15 
minutes for 3 times. Anti-rabbit or anti-mouse antibodies conjugated with 
horseradish peroxidase (HRP) (1:1000) in 2ml of 10% non-fat milk in TBS-T were 
added and incubated for 1 hour with constant shaking. The membrane was washed 
A 
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with TBS-T for 15 minutes for 3 times to wash the excessive secondary antibodies. 
Finally, enhanced chemiluminescence (ECL) detection reagents (Amersham) were 
used to develop the signal of the membrane. The emitting signal was detected by 
exposure to autoradiography film (Fuji). 
2.2.8 Glucose Uptake Assay 
I 1 • I Cells were seeded in 60mm culture dish. Two micromolar of AS2O3 was I 
f-i 
I added to the cells and incubated with various time. The medium was changed 
i 
•j 
everyday with drug replaced. After treatment, cells were harvested and washed twice 
with PBS. Then, 0.5ml of tritium-labeled reaction mixture containing 2|iCi/ml 
i 
！ 
o j H-2-deoxy-D-glucose (Amersham) and lOOjuM 2-deoxy-D-glucose (Sigma [ 
I 
Chemical Company) in PBS was added to the cells and incubated at 37°C for 15 
1 
minutes. The reaction was terminated by removing the reaction mixture. The cells 
were then washed twice by lOmM 2-deoxy-D-glucose in PBS. Finally, 2 0 0 j L i l of 
0.1% Triton X-100 was added to lyse the cells. One hundred fifty microliter of cell 
lysate was transferred to scintillation vials containing 1.5ml of scintillant. 
Radioactivity was recorded by Beckman LS7000 liquid scintillation counter. The 
remaining 50|li1 of lysate was used to determine the protein concentration by 
bicinchonic acid assay. 
A 
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The result of glucose uptake assay was expressed as the radioactivity (cpm) 
per [ig protein. 
2.2,9 ATP Production Assay 
Cells were seeded in 60mm culture dish. Two micromolar of AS2O3 was 
added to the cells and incubated for various time intervals. The medium was changed , 
I I 
everyday with drug replaced. After treatment, cells were harvested and washed twice 
with PBS. The cells were resuspended with 200|li1 of 12% trichloroacetic acid (TCA), 丨 
i 
i i 




5,000 X g for 10 minutes. Fifty microliter of supernatant was used to measure the 
amount of intracellular ATP level by a Sigma kit. Briefly, 1ml of PGA buffered 
solution and 1.7ml of distilled water were added to the reaction vial with preweighed 丨 
f 
I 
0.3mg of NADH and mixed well. Then 450jLil of the above solution was mixed with 
50|al of supernatant. The initial absorbance at 340nm was recorded with distilled 
water as blank. The reaction was initiated by adding 6.61\i\ of enzyme mixture 
containing glyceraldehydes 3-phosphate dehydrogenase and 3-phosphoglyceric 
phosphokinase. The decreased absorbance of NADH was recorded. 
The ATP amount was calculated with reference to a standard curve (Fig 2.1). 
Different concentrations of ATP were prepared and assessed by the kit. An ATP 
J 
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Standard curve was obtained by plotting the absorbance at 340nm against ATP 
concentration. 
The cell pellet was dissolved by adding 0.1% SDS and IM NaOH for 
determination of the protein concentration by bicinchonic acid assay. The 
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2 . 2 . 1 0 V i v o Study 
2.2.10.1 Animal Model 
Male or female Balb/c nu:nu nude mice aged 6-8 weeks were used as the 
animal model. The mice were fed with autoclaved tape water and ad libitum with 
animal diet (PICO LAB® Rodent Diet). The mice were housed in filter-top cages and 
were bred and kept at the Laboratory Animal Services Centre of The Chinese , 
University of Hong Kong under pathogen-free condition. 
2.2.10.2 Cell Line 
HepG2 cells were used. Cells at 4 x 10^  cells in 0.2ml of sterile PBS were 
inoculated to each mouse subcutaneously at the back. 
2.2.10.3 Treatment with Arsenic Trioxide 
The mice were divided into 3 groups, normal group (with no tumor cell 
inoculation and no drug treatment), negative control group (with tumor cell 
inoculation and without drug treatment) and AS2O3 treated group (with both tumor 
cell inoculation and drug treatment). For the negative control group and the AS2O3 
treated group, saline and 5mg/kg body weight of AS2O3 were injected to the mice 
intravenously via the tail vein, respectively. The drug was prepared by diluting the 
A 
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Stock of AS2O3 with sterile saline. Drug and saline of 0.2ml was injected to the mice. 
Treatment was started 2 days after inoculation of tumor cells. Then either 
drug or saline was injected to the mice every alternate day. The whole treatment 
lasted 3 weeks. 
2.2.10.4 Assessment of the Anti-Cancer Activity of Arsenic 
Trioxide 
At the end of the treatment, the tumor weight was measured and the volume 
of the tumor was monitored by a caliper. The tumor volume was calculated by the 
equation (Lew, et. al., 1999) shown as follows: 
Tumor volume (mm ) = a/2 x b/2 x h x tt 
where a is the minor dimension, b is the major dimension and h is the height 
2.2.10.5 Tissue Sample Preparation 
2.2.10.5.1 Preparation of Plasma 
Twenty to thirty milligram of pentobarbital (Sigma Chemical Company) in 
0.1-0.2 ml of saline was injected to each 
mouse. After the mouse was fainted, blood 
was drawn from its heart with a heparinized syringe. The blood was then centrifuged 
J 
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at 632 X g for 15 minutes at 4°C. Plasma appeared as a clear yellowish layer on the 
top. 
2.2.10.5.2 Preparation of Liver Tissue Homogenate 
Liver was taken from the mice after treatment. It was washed with the 




w/v) using two 10-second bursts of a Polytron PT 3100 homogenizer at 1 x 10^  rpm. 
A 10-second interval was allowed between the bursts in order to avoid overheating. 
i i 
2.2.10.5.3 Preparation of Cytosolic Fraction 
Cytosolic fraction was prepared by diluting the liver homogenate with the 
！ 
homogenizing buffer (1:3，v/v). The diluted mixture was centrifuged at 15000 x g for 
I 
30 minutes at A '^C. 
2.2.10.6 Measurement of the Plasma Enzyme Activity 
2.2.10.6.1 Plasma Creatine Kinase (CK) Activity, Plasma Lactate 
Dehydrogenase (LDH) Activity, Plasma Alanine Transaminase 
(ALT) Activity and Plasma Aspartate Transaminase (AST) 
Activity 
A 
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Plasma CK activity, LDH activity, ALT activity and AST activity were 
measured by CK kit, LDH-L kit, ALT kit and AST kit, respectively (Sigma Chemical 
Company). The procedure was according to the manufacturer protocol. For 
measuring the activity of CK, 20fal of the plasma sample was used. For measuring 
the LDH activity, 50|al of the plasma sample was used, while for measuring the ALT 
and AST activity, lOOjal of the plasma was used. The plasma sample was added to � 
• I 
！ i 
I 1ml of the corresponding reaction reagent in a cuvette and the reaction was j 
j. 
； ! I 
monitored at 30�C for both CK and LDH, while at 37�C for both ALT and AST. The ； 
•i J 




Plasma CK activity was calculated as follows: | !•‘ f i 
CK (U/L) = (AA per min x TV x 1000) = AA per min x 8200 I 
6.22 X LP X SV 
• 1 
Plasma LDH activity was calculated as followed: 
LDH (U/L) = (AA per min x TV x 1000) = AA per min x 3376 
6.22 X LP X SV 
Plasma ALT activity was calculated as followed: 
ALT (U/L) = (AA per minx TV X 1000) = AA per min x 1768 
6.22 X LP X SV 
J 
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Plasma AST activity was calculated as followed: 
AST (U/L) = (AA per min x TV x 1000) = AA per min x 1768 
6.22 X LP X SV 
where AA per min = change in absorbance per minute at 340mn 
TV = total reaction mixture volume (ml) 
SV = sample volume (ml) 
6.22 = millimolar absorptivity of NADH at 340nm 
I i j 
LP = lightpath 
1000 = conversion of units per ml to units per litre 
•i 
One unit of activity is defined as the amount of enzyme which produces 
I 




I 2.2.10.7 Preparation of Tissue for Light Microscopic Study 
The nude mice were sacrificed by cervical dislocation after treatment. Hearts 
and livers were removed immediately with care handling. The tissues were processed 
j 
by the procedures as shown below: 
I 
A 
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Procedures Reagents Time 
Liver Heart 
Fixing: 10% Buffered Formalin at least 2 days at least 2 days 
Processing: Dehydration 50% Ethanol 1.5 hours 1.5 hours 
70% Ethanol 1.5 hours 1.5 hours 
85% Ethanol 1.5 hours 1.5 hours 
95% Ethanol 2 hours 2 hours 
100% Ethanol 30 min 45 min � 
I 100% Ethanol 30 min 45 min 
I I 
100% Ethanol 30 min 45 min 
；( 
1 Clearing Xylene : Ethanol (1:1) 30 min 30 min 
Xylene 30 min 30 min | 
[ 
- 'i 
Xylene 30 min 45 min 
i 
Infiltration Paraffin wax 45 min 1.5 hours 
Paraffin wax 45 min 1.5 hours 
Embedding: Tissues were embedded in paraffin wax 
Sectioning: Tissues were cut into sections of 5 jam in thinckness 
Staining: Dewax Xylene 5 min 5 min 
Xylene 5 min 5 min 
Hydration 100% Ethanol 1 min 1 min 
95% Ethanol 1 min 1 min 
70% Ethanol 1 min 1 min 
50% Ethanol 1 min 1 min 
30% Ethanol 1 min 1 min 
A 
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Running tap water 1 min 1 min 
Staining Harris' hematoxylin 7 min 6 min 
Running tap water 1 min 1 min 
Acid ethanol 15 sec 15 sec 
Running tap water 1 min 1 min 
Scott's tap water 2 min 2 min 
Running tap water 1 min 1 min 
0.5% aqueous Eosin 2 min 3 min 
Running tap water 1 min 1 min 
Dehydration 70% Ethanol as short as possible 
95% Ethanol as short as possible 
100% Ethanol 2 min 2 min 
100% Ethanol 2 min 2 min 
Xylene:Ethanol (1:1) 2 min 2 min 
Xylene 2 min 2 min 
Xylene 2 min 2min 
Mounting: Slides were mounted with Canada Balsam 
The slides were observed under light microscope (Nikon Microphot-FX). 
The pictures of the liver and the heart sections under microscope were taken for 
record and comparison. 
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2.2.10.8 Measurement of the Basal Reduced Glutathione (GSH) 
Level of Liver Tissue 
Twenty hundred microliter of tissue homogenate was mixed with lOO i^l of 
cold 25% (w/v) trichloracetic acid (TCA) and 200|al of saline. The reaction mixture 
was centrifuged at 632 x g for 10 minutes at 4�C. The supernatant was collected and 
mixed with 1ml of O.IM phosphate buffer (pH 8). The colour reaction was initiated 
by adding 50|li1 of 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB) (Sigma Chemical 
Company) solution (3mM, prepared by dissolving in the same phosphate buffer). The 
absorbance at 412nm was measured after 15 minutes. The basal GSH level was 
estimated from a calibration curve (Fig. 2.2.) using GSH (Sigma Chemical Company) 
as standard and was calculated as follows: 
Basal GSH level (nmole/mg tissue) = A412 
Slope X Wt 
where A412 = absorbance at 412nm 
Slope = slope of standard curve 
Wt = total weight of tissue used (mg) 
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Fig. 2.2 Calibration curve of GSH. 
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2.2.10.9 Measurement of the Activity of Antioxidant Enzyme, 
Glutathione S-Transferase (GST) of Liver Tissue 
Reaction mixture contained 1ml of phosphate buffer (O.IM sodium 
phosphate-lM EDTA, pH 6.5)，50|al of GSH (Sigma Chemical Company) and 50|il 
of IM 1 -chloro-2,4-dinitrobenzene (CDNB) dissolved in 95% ethanol. The reaction 
was initiated by adding 20|al of cytosolic fraction. The changes in absorbance at 
340nm was monitored spectrophotometrically for 2 minutes at 30°C. The enzyme 
activity of GST was calculated as follows: 
GST (U/mg tissue) = AA per min x TV x 1000 
9.6 X Wt 
where AA per min = change of absorbance per minute at 340nm 
TV = total volume of reaction mixture (ml) 
1000 = conversion of units per ml to units per liter 
Wt = total weight of tissue used (mg) 
9.6 = millimolar absorptivity of CDNB at 340nm 
One unit of enzyme activity is defined as the amount of enzyme which 
reduces 1 |amole of CDNB per minute under the condition of assay procedure. 
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For in vitro study, the same experimental procedure was applied and the 
activity of GST was calculated by the same equation. 
2.3 Statistical Analysis 
All experiments were performed in triplicate unless otherwise noted. The 
results were expressed as mean 土 standard deviation. Student's T-test was performed 
in the experiment indicated and p<0.05 was considered as statistically significant. 
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Cfidpter 3 
In Vitro Stiufy of Arsenic 
THo^e on JLcute 
^omyelbcytic Leu^mia CeCC 
Line,痛 
3.1 Introduction 
As a purified solid compound, arsenic trioxide (AS2O3) must be dissolved to 
give a solution before performing any experiments. In fact, different researchers used 
different buffers to prepare the AS2O3 stock solution. For instance, some simply used 
water (Lew, et al, 1999) and some used NaOH (Gianni, et al., 1998 and Perkins, et 
al., 2000). Nevertheless, most researchers used PBS to dissolve AS2O3. In view of 
this, I used PBS to prepare the AS2O3 stock. 
In order to compare my preparation of drug with others as well as to confirm 
the effect of AS2O3 on acute promyelocytic leukemia (APL), in vitro experiments 
were carried out with APL cell line, NB-4. 
The effect of AS2O3 on cell proliferation of NB-4 cells was tested by MTT 
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assay. The action mechanism of AS2O3 was widely studied. Induction of apoptosis 
was believed to be one of the key pathways for AS2O3 to exert its effect. In my 
project, induction of apoptosis was examined by a more advanced and precise 
method, flow cytometry with Annexin V-PI staining. 
3.2 Principle of Flow Cytometry with Annexin V-PI Staining 
Flow cytometry with Annexin V-PI staining allows us to identify the 
apoptotic cells from the necrotic cells. This method makes use of 2 different dyes, 
Annexin V conjugated with FITC and PI, which have different properties. Annexin V 
is a protein which can recognize phosphatidylserine (PS) and bind to it. However, 
Annexin V itself cannot emit any signal. Thus, FITC is conjugated on it. On the other 
hand, PI emits signal once it intercalates DNA. Therefore, different patterns of 
signals from the dot plot in which the intensity of PI is plotted against that of the 
Annexin V-FITC allow us to identify the apoptotic cells from the necrotic cells (Fig. 
3.1). 
Under normal condition, most cells accumulate in the left bottom quadrate of 
the dot plot (Fig 3.1a). The cells are viable and the cell membrane is intact. Therefore, 
both Annexin V-FITC and PI cannot enter the cells and give no signal. As a result, 
low intensity of both Annexin V-FITC and PI is obtained and indicated in the left 
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bottom quadrate. 
Apoptotic cells are indicated in the right bottom quadrate (Fig 3.1b). When 
apoptosis occurs, one of the components of the cell membrane, PS, will flip from the 
inner membrane to the outer membrane. The exposure of PS allows Annexin V-FITC 
to bind on it and then, the bound Annexin V-FITC emits signal. During apoptosis, 
mostly the early apoptosis, the cell membrane still remains intact. Therefore, PI 
cannot enter the cells and emits no signal. As a result, apoptotic cells are 
characterized with high intensity of Annexin V-FITC and low intensity of PL Such 
population is shown in the right bottom quadrate of the dot plot. 
For necrotic cells or late apoptotic cells, they are shown in the right upper 
quadrate of the dot plot (Fig 3.1c). When necrosis or late apoptosis takes place, the 
integrity of the cell membrane can no longer be maintained. Thus, both dyes can 
enter the cells and emit signal. As a result, high intensity of both Annexin V-FITC 
and PI is obtained. Such population is indicated in the right upper quadrate. 
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Fig 3.1 The schematic diagram of the principle of flow cytometry with Annexin 
V-PI staining to identify apoptotic cells from necrotic cells, a) Cells under normal 
condition, b) Apoptosis occurs, c) During necrosis or late apoptosis. 
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3.3 The Effect of Arsenic Trioxide on Cell Proliferation of NB-4 
Cells 
The research of AS2O3 becomes more and more popular after the discovery of 
its amazing effect on treating leukemia. Among various types of leukemia, acute 
promyelocytic leukemia (APL) is found to be the most sensitive toward AS2O3. In my 
project, I examined the effect of AS2O3 toward APL cell line, NB-4, by MTT assay 
first. 
The MTT assay showed that AS2O3 inhibited the cell proliferation of NB-4 
cells in a dose-dependent manner (Fig. 3.2). The IC50 of As203on NB-4 cells after 
24-hour incubation was about 2|LIM. 
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Fig. 3.2 The effect of AS2O3 on cell proliferation of an APL cell line, NB-4. NB-4 
cells were incubated with various concentrations of AS2O3 (0-20|LIM) for 24 hours 
and cell viability was examined by MTT assay. The IC50 of AS2O3 on NB-4 cells after 
24-hour incubation was about 2|LIM. 
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3.4 Study of the Action Mechanism of Arsenic Trioxide upon 
Treatment of NB-4 Cells 
The action mechanism of AS2O3 is widely studied. Apart from induction of 
differentiation (Chen, et al., 1997a，Chen, et al., 1997b and Gianni, et al.，1998), 
induction of apoptosis is an important pathway. 
In my project, induction of apoptosis of NB-4 cells upon AS2O3 treatment was 
confirmed by the use of flow cytometry with Annexin V-PI staining. NB-4 cells were 
incubated with various concentration of AS2O3 for 24 hours. The dot plots with the 
intensity of PI against that of Annexin V-FITC were drawn (Fig 3.3). From the 
figures, the cell population of control, i.e. with no AS2O3 addition, was accumulated 
in the left bottom quadrate. Upon treatment with AS2O3, the cell population shifted to 
the right bottom quadrate. This indicated apoptosis occurred. The dot plots also 
showed that the percentage of apoptotic cells increased with increasing 
concentrations of AS2O3. And, as low as 0.5|LIM of AS2O3, apoptosis could still occur. 
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Fig 3.3 The dot plots with the intensity of PI against that of Annexin V-FITC. 
NB-4 cells were treated with various concentrations of AS2O3 (0.5-2)LIM) for 24 hours. 
A shift in cell population to the right bottom quadrate was observed upon AS2O3 
treatment by flow cytometry with Annexin V-PI staining. 
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3.5 Summary 
The cytotoxic effect of AS2O3 on NB-4 cells as expected by other researchers 
was reproducible. From the result of the present study, AS2O3 was capable to inhibit 
the cell proliferation of NB-4 cells in a dose-dependent manner and the IC50 of AS2O3 
on NB-4 cells after 24-hour incubation was about 2jaM. Moreover, AS2O3 probably 
exerted its effect via induction of apoptosis. 
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CUcipter 4 
In Vitro Study of Arsenic 
Tnoj(i([e on Tfuman 
yfepatoceHuCar Carcinoma Cell 
Line, ！ffepgz 
4.1 Introduction 
Arsenic trioxide (AS2O3) is effective in treating leukemia, especially acute 
promyelocytic leukemia (APL). In fact, AS2O3 is effective not only on treating 
leukemia, but also on solid tumors. It was reported that the therapeutic concentration 
of AS2O3 (0.5-2|LIM) inhibited the growth of gastric cancers (Zhang, et al., 1999 and 
Jiang, 2001)，neuroblastoma (Akao, et al., 1999 and Ora, et al., 2000), esophageal 
carcinoma (Shen, et al., 2000) as well as head and neck cancers (Seol, et al., 1999). 
Moreover AS2O3 was shown to be effective in the treatment through the induction of 
apoptosis or cell cycle arrest. In my project, I examined the effect of AS2O3 on 
hepatocellular carcinoma. 
In this chapter, the effect of AS2O3 on hepatocellular carcinoma was examined 
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by in vitro experiments. The cell line, HepG2, was used. The effect of AS2O3 on cell 
proliferation was first to be examined by MTT assay. The action mechanism of 
AS2O3 was then studied. The concentration for the mechanism study was fixed to 
2\xM which is a clinically achievable concentration. Trypan blue exclusion assay was 
performed to assess the cytotoxicity of AS2O3 at the clinically achievable 
concentration, i.e. 2\xM, on HepG2 cells. Analysis of cell-cycle phase distribution , 
i 
I 
was performed by flow cytometry with PI staining in order to study the 
1: 
I anti-proliferative effect of AS2O3. To study whether AS2O3 was capable in inducing 
I 
apoptosis, DNA fragmentation assay and flow cytometry with Annexin V-PI staining 
were carried out. The study of the mechanism of apoptotic pathway was performed. 
I 
Activation of caspase cascade was examined by Western analysis of caspase-3 and, 
participation of mitochondria in apoptosis was examined by detecting the change of 
mitochondrial membrane potential by flow cytometry as well as the release of 
cytochrome c by Western analysis. 
Apart from induction of apoptosis, other action mechanisms may be involved. 
I focused on the effect of AS2O3 on glucose metabolism. Firstly, the effect of AS2O3 
on the expression of glucose transporters (Gluts) was examined by Western analysis. 
Then the change in glucose uptake and ATP production upon AS2O3 treatment were 
studied by glucose uptake assay and ATP kit, respectively. 
A 
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4.2 The Effect of Arsenic Trioxide on Cell Proliferation of HepG2 
Cells by MTT Assay 
The effect of AS2O3 on cell proliferation of HepG2 cells was first examined 
by MTT assay. HepG2 cells were incubated with various concentrations of AS2O3 and 
incubated for 1, 3，5 and 7 days (Fig 4.1). The results showed that AS2O3 inhibited the 
cell proliferation of HepG2 cells in a dose- and time-dependent maimer. The IC50 of 
AS2O3 on HepG2 cells after 1-day incubation was greater than 20|LIM. However, the 
I C 5 0 dropped dramatically to 3.9|AM, 2.2|LIM and 1.4)LIM after 3-，5- and 7-day 
incubation time periods, respectively. 
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Fig 4.1 The effect of AS2O3 on cell proliferation of HepG2 cells by MTT assay. 
HepG2 cells were treated with various concentrations of AS2O3 and incubated for 1,3, 
5 and 7 days. The I C 5 0 of AS2O3 on HepG2 cells was >20ILIM, 3.9|LIM, 2.2|LIM and 
\A\iM for 1- 3-，5- and 7-day incubation, respectively. 
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4.3 The Effect of Arsenic Trioxide on HepG2 Cells at Clinically 
Achievable Concentration 
AS2O3 has been used in clinical trials of APL (Zhang, et al., 1996，Shen, et al., 
1997，Sun, et al., 1997，Soignet, et a l , 1998 and Niu, et a l , 1999) for years. The 
dosage for clinical trials was lOmg/day. It was found that this dosage was effective in 
induction of complete remission of both the newly diagnosed and relapsed patients. 
The pharmacokinetic study showed that the steady state of plasma arsenic 
concentration was 0.5-2|iM (Shen, et al., 1997). In my project, therefore, the 
concentration of AS2O3 used in in vitro studies was fixed to 2JLIM in order to keep 
with the in vivo plasma level and this concentration has been constantly used in other 
i in vitro studies. 
i 
！ j 
4.3.1 The Cytotoxicity of Arsenic Trioxide on HepG2 Cells by 
Trypan Blue Exclusion Assay 
AS2O3 was found to be effective in inhibiting the cell proliferation of HepG2 
cells and the IC50 dropped to the clinically achievable concentration upon 5-day 
treatment. To further study the effect of AS2O3 at the clinically achievable 
concentration on HepG2 cells, trypan blue exclusion assay was carried out. 
The percentage of control began to drop only after 5-day incubation with 
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AS2O3 (Fig 4.2a). Upon 1- and 3-day incubation with AS2O3, the percentage of 
control was greater than 90%. However, treatment with AS2O3 for 5 days decreased 
the percentage of control dramatically to about 17%. The percentage of control 
remained nearly the same even upon further incubation with AS2O3. 
The percentage of viability was also found and this may shed some light on 
the anti-proliferative mechanism of AS2O3 on HepG2 cells. The result (Fig 4.2b) 
showed that the percentage of viability of treated HepG2 cells remained high upon 
the first 3-day treatment with AS2O3. It dropped significantly to about 20% after 
i 
5-day incubation and further decreased to about 12% upon 7-day treatment. This 
result indicated that AS2O3 exerted cytotoxic effect on HepG2 cells because the : 
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Fig 4.2 The effect of AS2O3 at clinically achievable concentration, i.e. on 
HepG2 cells by trypan blue exclusion assay. HepG2 cells were treated with 2|LIM 
of AS2O3 for 1，3, 5 and 7 days and the results were expressed in terms of percentage 
of control (a) and percentage of viability (b). 
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4.3.2 The Effect of Arsenic Trioxide on Cell-Cycle Phase 
Distribution 
From the results of MTT assay and the trypan blue exclusion assay, AS2O3 
inhibited the growth ofHepG2 cells possibly by cytotoxic effect. To further study the 
anti-proliferative effect of AS2O3 on HepG2 cells, whether AS2O3 acts through cell 
cycle arrest or cytotoxic effect, cell-cycle phase distribution using flow cytometry 
with PI staining was carried out. 
j i 
Fig 4.3 showed a typical histogram of cell-cycle phase distribution of cells 
which are normal or without any treatment. The first peak represents 1 copy of DNA 
which indicates GO/Gl phase. The second peak represents 2 copies of DNA which | 
j 
indicates G2/M phase. The in-between plateau indicates S phase at which cells have 
1-2 copies of DNA. 
Fig 4.4 showed the result of a typical experiment. Upon AS2O3 treatment, 
there was no obvious alternation of each cell cycle phase when compared with the 
control. Nevertheless, sub-Gl peak appeared when the cells were treated with AS2O3 
for 3 days. The percentage of cells in the sub-Gl phase increased upon longer 
incubation period. 
In conclusion, AS2O3 inhibited the cell proliferation of HepG2 cells was not 
due to cell cycle arrest, but due to cytotoxic effect. 
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Fig 4.3 A typical histogram of cell cycle analysis of cells which are normal or 
without any treatment. 
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Fig 4.4 Results of cell-cycle phase distribution of HepG2 cells treated with 
of AS2O3 for 1，3，5 and 7 days by flow cytometry with PI staining. There was no 
obvious alternation of each cell-cycle phase when compared with the control. 
Sub-Gl peak appeared upon treatment with AS2O3 for 3 days or above. 
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4.3.3 The Underlying Mechanism of the Cytotoixic Effect of 
Arsenic Trioxide — Necrosis or Apoptosis? 
AS2O3 inhibited the cell proliferation of HepG2 cells probably by cytotoxic 
effect. However, the underlying mechanism of such cytotoxic effect is not well 
known. For example, whether it simply brings on necrosis or induces apoptosis 
needed to be studied. In this section, DNA fragmentation assay and flow cytometry , 
with Annexin V-PI staining were carried out to examine whether AS2O3 exhibits its 
effect via apoptosis or necrosis. 
I 
4.3.3.1 DNA Fragmentation Assay ； 
！ 
！ 
A ladder pattern shown in the DNA gel electrophoresis is a phenomenon of | 
apoptosis. During apoptosis, caspase-activated deoxyribonuclease (CAD) is activated 
and cleaves the DNA into 30-500 kilo base-pair domain-sized fragments. Most low 
molecular weight fragments are multiples of about 200 base-pair. This is due to the 
cleavage of DNA at the linker between nucleosomes (Reed, 2000 and Hengartner, 
2000). As a result, after applying gel electrophoresis, a ladder pattern is observed 
which indicates apoptosis takes place. 
i 
Chapter 5 p. 100 




Fig 4.5 Result of DNA fragmentation assay by AsiOs treatment. HepG2 cells 
I 
i 
were treated with 2|LIM of AS2O3 for 1,3, 5 and 7 days. A ladder pattern was observed 
upon 5- and 7-day treatments. Lane M: 100 base-pair marker; lane 1: control; lane 2: 
1-day treatment; lane 3: 3-day treatment; lane 4: 5-day treatment and lane 5: 7-day 
treatment. 
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Fig 4.5 showed the result of DNA fragmentation assay in a typical experiment. 
V When HepG2 cells were treated with 2|LIM of AS2O3，a typical ladder pattern was 
observed upon 5- and 7-day treatment. 
4.3.3.2 Flow Cytometry with Annexin V-PI Staining 
Induction of apoptosis of HepG2 cells upon AS2O3 treatment was further 
confirmed by flow cytometry with Annexin V-PI staining. 
I 
From the dot plots (Fig 4.6) of a typical experiment, there was a shift in cell 
population to the right bottom quadrate upon AS2O3 treatment, in turn, indicated • 
j 
apoptosis occurred. The dot plots also showed that the percentage of apoptotic cells ！ 
i 
i i increased with increasing the incubation time periods, from 4.8% in control to 16.4% | 
1 i 
in 7-day treatment. This showed that treatment of HepG2 cells with 2|LIM of AS2O3 
exhibited increases in degrees of apoptosis in a time-dependent manner. 
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Fig 4.6 The dot plots with the intensity of PI against that of Annexiv V-FITC. 
HepG2 cells were treated with 2iiiM of AS2O3 for 1, 3, 5 and 7 days. A shift of cell 
population to the right bottom quadrate was observed upon AS2O3 treatment by flow 
cytometry with Annexin -PI staining. 
J 
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4.3.3.3 Brief Conclusion 
V Both results in DNA fragmentation assay and flow cytometry with Annexin 
V-PI staining indicated that AS2O3 exerted its effect via induction of apoptosis. 
However, the action of AS2O3 at clinically achievable concentration, i.e. 2\xM, was 
effective in induction of apoptosis of HepG2 cells only upon 5-day or a longer 
incubation time period 
I I I i I i 
i 
i. i 
1 j 4.3.4 The Study of the Mechanism of Apoptotic Pathway 
Apoptosis is an important cellular event. It allows the organism to tightly 
i 
control cell numbers and tissue size, as well as to protect them from rogue cells 
which threaten homeostasis. It is a complicated but tightly controlled program. 
Briefly, apoptosis can be triggered by the caspase cascade and through the ！ 
participation of mitochondria (Hengartner, 2000). Thus, in this section, the 
mechanism of apoptotic pathway induced by AS2O3 was studied. The involvement of 
caspase cascade was examined by Western analysis of caspase-3. On the other hand, 
the participation of mitochondria in apoptosis was examined by detecting the change 
in mitochondrial membrane potential and the release of cytochrome c from 
mitochondria by flow cytometry with JC-1 staining and Western analysis, 
respectively. 
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4.3.4.1 Activation of Caspase-3 upon Arsenic Trioxide Treatment 
Caspases can be considered as the central executioner of apoptosis because 
they bring about most of the visible changes that characterize apoptotic cell death. 
Different caspases carry out different functions. Some amplify the apoptotic signals 
while some serves as a cofactor to associate with a protein to make an active form. 




amplify and integrate the apoptotic signal as well as activate the caspase-activated I 
deoxyribonuclease (CAD), which results in DNA fragmentation (Thombeny, et al., 
1998 and Hengartner, 2000). Therefore, I examined the involvement of caspase | 
cascade in AS2O3-induced apoptosis by Western analysis of caspase-3. 
i 
From the Western analysis (Fig 4.7) of a typical experiment, a band with size 
32kDa was observed even in the control. This was the precursor of caspase-3, 
procaspase-3. Upon treatment with 2jLiM of AS2O3 for 5 days, the density of 
procaspase-3 became weaker with the appearance of another band representing 
17kDa. This should be the cleaved caspase-3. Cleavage of procaspase-3 indicated 
activation of caspase-3, in turn, indicated the involvement of caspase-3 in 
AsiOs-induced apoptosis. 
/ 
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Fig 4.7 Western analysis of caspase-3 upon treatment with lyM of AsiOs for 1，3， 
5 and 7 days. The band with size 32kDa was the precursor of caspase-3, 
procaspase-3 while the band with size 17kDa should be the cleaved caspase-3. Lane 
1： control; lane 2: 1-day treatment; lane 3: 3-day treatment; lane 4: 5-day treatment 
and lane 5: 7-day treatment. 
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4.3.4.2 The Participation of Mitochondria in Arsenic 
Trioxide厨Induced Apoptosis 
Mitochondria play an important role in apoptosis (Green, et al., 1998 and 
Hengartner, 2000). Disruption of the mitochondrial membrane potential and release 
of cytochrome c to the cytosol can be considered as the major phenomenon at which 
mitochondria participate in the induction of apoptosis. In this section, the change in , 
] 
\ - I the mitochondrial membrane potential upon AS2O3 treatment was monitored by flow I 
cytometry with JC-1 staining while the release of cytochrome c to the cytosol was ：丨 
i 
i j 
detected by Western analysis，so whether mitochondria participated in the 
AsiOs-induced apoptosis could be examined. 
4.3.4.2.1 The Change in Mitochondrial Membrane Potential upon 
Arsenic Trioxide Treatment 
The change in mitochondrial membrane potential (Acpm) was examined by 
flow cytometry with JC-1 staining. JC-1 is a fluorescent dye which can exist in the 
form of monomer or dimer. When the membrane potential is low, JC-1 exists in 
monomer form and emits green fluorescence, while when the membrane potential is 
higher，JC-1 exists in dimer form and emits red fluorescence at higher membrane 
potential (Catalogue of Molecular Probes). Thus, JC-1 can be used to indicate the 
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I change of mitochondrial membrane potential. Under normal condition, the 
\ membrane potential of mitochondria is maintained. Thus, cells with low green 
fluorescence are observed (Fig 4.8a). However, when the mitochondrial membrane 
potential is disrupted, cells with increased green fluorescence are observed. As a 
result, a shift in cell population to the right is observed and such population is shown 
in the region marked with R1 (Fig 4.8b). 
i 









2|aM of AS2O3 even for 7 days. The cell population in region R1 was about the same 
throughout the treatment. Positive control was made by adding FCCP to the sample 
(final concentration of FCCP was 50|aM) before incubation with JC-l. In the positive 
control, the mitochondrial membrane potential was disrupted in 70% of the cells 
t 
A 
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Fig 4.8 Assessment of the mitochondrial membrane potential by flow cytometry 
with JC-1 staining, a) Cells under normal condition and the mitochondrial 
membrane potential is maintained, b) The mitochondrial membrane potential is 
disrupted and cells locating within region R1 are those with collapsed mitochondrial 
I membrane potential. 
A 
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Fig 4.9 Results of the change in mitochondrial membrane potential upon 
treatment with 2iJ,M of AS2O3 for 1，3，5 and 7 days by flow cytometry with JC-1 
staining. Positive control was made by addition of FCCP to a final concentration of 
50|LIM before incubation with JC-1. 
j 
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4.3.4.2.2 The Study of the Release of Cytochrome C from the 
Mitochondria to Cytosol upon Treatment with Arsenic Trioxide 
Normally, cytochrome c is restricted in the mitochondria. It may be released 
to the cytosol under two conditions. First, they are released when necrotic process 
takes place because of the collapse of electron transport chain. Second, they are 
released when apoptosis occurs (Green, et al., 1998). As I have demonstrated that 
I. apoptosis occurred when HepG2 cells were treated with AS2O3, any release of I 
i 
！ 
cytochrome c was not probably due to the first reason, i.e. necrosis. Thus, the release 
of cytochrome c from the mitochondria to the cytosol was probably due to the 
involvement of mitochondria in the AS2O3-induced apoptosis. 
i From the Western analysis (Fig 4.10), no band occurred at the molecular size 
j 
of 15kDa, except in the positive control. This indicated that no cytochrome c was 
released to the cytosol. The positive control was made by adding 2 0 0 j L i g / 5 0 j L i l 
digitonin to the cells which can disrupt the mitochondrial membrane and release the 
cytochrome c to the cytosol. 
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Fig 4.10 Western analysis of the release of cytochrome c from the mitochondria 
to the cytosol in the As203-induced apoptosis. HepG2 cells were treated with 2|LIM 
of AS2O3 for 1, 3, 5 and 7 days. Lane 1: control; lane 2: 1-day treatment; lane 3: 
3-day treatment; lane 4: 5-day treatment; lane 5: 7-day treatment and lane 6: positive 
control prepared by adding 200|Lig/50|Lil digitonin. 
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4.3.4.2.3 Brief Conclusion 
V AS2O3 did not alter the mitochondrial membrane potential nor cause the 
release of cytochrome c from the mitochondria to the cytosol, even upon 7-day 
treatment. It can be concluded that AS2O3-induced apoptosis did not involve the 
participation of mitochondria. 
I 
I 
I i 4.4 Arsenic Trioxide Mediated Its Effect via Other Action i I 
Mechanisms 
From the above study, AS2O3 was shown to be effective in inhibiting the 
growth ofHepG2 cells via induction of apoptosis, independent of the involvement of 
I 
mitochondria. In fact, did AS2O3 mediate its effect via other action mechanisms? In 
i 
this section, the effect of AS2O3 on glucose metabolism was studied. 
The growth of cancer cells is much faster than that of the normal cells. The 
faster proliferation rate is accompanied by the increased energy utilization. Since 
energy mainly derives from glucose, much more glucose is required for the 
development of tumor (Chan, et al, 1983). The increased glucose uptake is mediated 
by the overexpression of glucose transporters (Gluts) (Yamamto, et al., 1990, Younes, 
et al.，1996 and Au, et al., 1997). Therefore, interference of Glut expression (Chan, et 
al., 1999 and Liong, et al., 1999), glucose uptake and/or glucose metabolism of 
Chapter 4 
cancer cells (Chan, et al, 1999 and Liong, et al., 1999) inhibit the growth of tumors. 
In view of this, I studied the effect of AS2O3 on glucose metabolism by examining the | 
expression of Gluts 1 and 2, which are housekeeping and liver-specific Gluts, 
respectively, glucose uptake as well as ATP production upon treatment with AS2O3. 
4.4.1 The Effect of Arsenic Trioxide on the Expression of Glucose 
Transporters 1 and 2 
i 
Energy independent transport of glucose down its concentration gradient is 
mediated by Gluts. In fact, there are 7 isoforms of Gluts which exhibit tissue-specific 
distribution. Glut 1 can be considered as a housekeeping Glut because it expresses at 
highest level and in many tissues, while Glut 2 is liver specific (Pessin, et al., 1992, 
Bell, et al, 1993 and Muecker, 1994). In this section, the effect of AS2O3 on the 
expression of Gluts 1 and 2 in HepG2 cells was studied by Western analysis. 
From the results of typical experiments, the expression of both Gluts 1 (Fig 
4.11) and 2 (Fig. 4.12) did not change upon treatment with 2jLiM of AS2O3 in HepG2 
cells. 
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Fig 4.11 Western analysis of Glut 1 in HepG2 cells upon treatment with 2|LIM of 
AS2O3 for 1，3，5 and 7 days. Lane 1: control; lane 2: 1-day treatment; lane 3: 3-day 
treatment; lane 4: 5-day treatment and lane 5: 7-day treatment. 
I 
J 
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Fig 4.12 Western analysis of Glut 2 in HepG2 cells upon treatment with of 
AS2O3 for 1，3，5 and 7 days. Lane 1: control; lane 2: 1-day treatment; lane 3: 3-day 
treatment; lane 4: 5-day treatment and lane 5: 7-day treatment. 
1 
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4.4.2 The Effect of Arsenic Trioxide on Glucose Uptake 
V Although AS2O3 did not affect the expression of Gluts in HepG2 cells, it may 
affect the function of the Gluts. Thus, the effect of AS2O3 on glucose uptake was 
examined by the use of tritium-labeled 2-deoxy-D-glucose. The result showed that 
AS2O3 inhibited the glucose uptake in a time-dependent manner and the differences 
between control and 5-day treatment, as well as control and 7-day treatment, were 
statistically significant (Fig 4.13). 
- • 1 I 
I 
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Fig 4.13 The effect of AS2O3 on glucose uptake in HepG2 cells by the use of 
tritium-labeled 2-deoxy-D-glucose. HepG2 cells were treated with 2jLiM of AS2O3 
for 1, 3, 5 and 7 days. The glucose uptake level of the control was set as 100%. 
* p < 0.05 
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4.4.3 The Effect of Arsenic Trioxide on ATP Production 
V ATP is the energy equivalent of the cells. It is produced by means of 
glycolysis as well as TCA cycle. Interference of ATP production definitely hinders 
the growth of the cells. In this section, the effect of AS2O3 on the production of ATP 
in HepG2 cells was studied by a Sigma kit. 
The result showed that AS2O3 statistically significantly inhibited the ATP 
！ I 
I I production of HepG2 cells in a time-dependent manner (Fig. 4.14). j 
I 
i I 
4.4.4 Brief Conclusion 
The effect of AS2O3 on glucose metabolism of HepG2 cells was studied by 
examining the expression of Gluts 1 and 2, glucose uptake as well as ATP production. 
The result showed that AS2O3 had no effect on the expression of Gluts 1 and 2. 
However, it inhibited the glucose uptake and ATP production in a time-dependent 
manner. The effect on interference of ATP production was greater than that of 
glucose uptake. 
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Fig 4.14 The effect of AS2O3 on the production of ATP in HepG2 cells by a Sigma 
kit. HepG2 cells were treated with 2JLIM of AS2O3 for 1, 3, 5 and 7 days. The ATP 




V AS2O3 was effective in inhibiting the cell proliferation of HepG2 cells in a 
dose- and time-dependent manner. The IC50 of AS2O3 on HepG2 cells upon 1-, 3-, 5-
and 7-day treatment was >20|LIM, 3.9)IM, 22\xM and 1.4|LIM, respectively. On the 
other hand, AS2O3 at the clinically achievable concentration, i.e. 2\iM, inhibited the 
cell proliferation of HepG2 cells via induction of apoptosis, but the inhibition was 
i i 
！ 
independent of the involvement of mitochondria. In addition, AS2O3 interfered with 
I — 
the glucose metabolism by inhibiting the function of Gluts, i.e. glucose uptake, as 
well as ATP production. 
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From the in vitro study, arsenic trioxide (AS2O3) was shown to be effective in 
treating human hepatocellular carcinoma cell line, HepG2. The results showed that 
AS2O3 acted through the induction of apoptosis without participation of mitochondria. 
Moreover, it interfered with glucose metabolism in the cells. In this chapter, the 
effect of AS2O3 on the growth of hepatocellular carcinoma was further studied by in 
vivo experiments. 
For the in vivo study, HepG2-bearing nude mice were used. The anti-tumor 
activity of AS2O3 was studied by measuring the tumor volume and the tumor weight 
after the whole course of treatment. Moreover the probable adverse effect of AS2O3 
toward normal tissues was investigated by morphological study as well as 
measurement of the release of tissue-originated enzymes in the plasma of the host. In 
Chapter 51^.91 
addition, involvement of the glutathione (GSH) redox system upon treatment with 
( AS2O3 was studied by measuring the basal GSH level, as well as the activity of 
glutathione S-transferase (GST) of the liver tissue. 
5.2 Treatment with Arsenic Trioxide 
Nude mice were used in the in vivo study (Fig 5.1a). The mice were divided 
into 3 groups, normal group which had no tumor cell inoculation and no drug 
treatment, negative control group which had HepG2 cells inoculation with no drug 
but saline injection, and AS2O3 treated group which had both HepG2 cells inoculation 
and 5mg/kg AS2O3 injection. For the negative control and AsiOs-treated groups, 
about 4 X 106 cells were inoculated to the mice subcutaneously. Two days after 
inoculation of tumor cells, a solid tumor was observed at the back of the nude mice 
(Fig 5.1b). The treatment was then started and lasted for 3 weeks. 
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Fig 5.1a) Nude mice aged 6-8 weeks, b) HepG2 cells at 4 x 10^  were inoculated to 
the nude mice subcutaneously at the back and a solid tumor was observed 2 
days after inoculation. 
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5.3 Assessment of the Anti-Tumor Activity of Arsenic Trioxide 
The anti-tumor activity of AS2O3 was assessed by measuring the tumor 
volume and the tumor weight after the whole course of treatment. 
From the figures (Fig. 5.2a and b) of typical experiments, the size of the 
tumor of the negative control group and the treated group differed significantly. By 
measuring the size with a caliper, the volume of tumor was calculated. The result 
showed that the tumor volume of the treated group was much smaller than that of the 
negative control group (Fig 5.3). The tumor volume of the negative control group 
was set as 100%. Comparing with the control, the tumor volume was about 3%. In 
other words, there was a reduction of tumor volume of over 95%. 
The tumor weight was also measured after the whole course of treatment. 
Similar result as that in the tumor volume was found (Fig. 5.4). The tumor weight of 
the treated group was much smaller than that of the negative control group. 
Comparing with the control, there was a significant reduction in tumor weight. 
In conclusion, AS2O3 caused statistically significant reductions in both the 
tumor volume and the tumor weight. Thus, AS2O3 exhibited anti-tumor activity on 
HepG2-bearing nude mice. 
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Fig 5.2 Photographs showing the tumor size after the whole course, 3 weeks, of 
treatment, a) Negative control group injected with saline, b) AS2O3 treated group 
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Fig 5.3 The effect of AS2O3 on the tumor volume. The tumor volume of the 
HepG2-bearing nude mice was measured after the whole course of treatment. The 
negative control group was injected with saline while the AsaOs-treated group was 
injected with 5mg/kg AS2O3 every alternate day for 3 weeks. The tumor volume was 
calculated by the formula: a/2 x b/2 x h x tt, where a, b and h are the minor and major 
dimensions and height, respectively (Lew, et al, 1999). * p < 0.05. 
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Fig 5.4 The effect of AS2O3 on the tumor weight. The tumor weight of the 
HepG2-bearing nude mice was measured after the whole course of treatment. The 
negative control group was injected with saline while the AS2O3-treated group was 
injected with 5mg/kg AS2O3 every alternate day for 3 weeks. * p = 0.001. 
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5.4 The Effect of Arsenic Trioxide toward Normal Tissues 
AS2O3 exhibited strong anti-tumor activity. On the other hand, AS2O3 was 
reported to be toxic. Arsenic trioxide was once claimed to be the poison of poisons 
(Goby, 1994). It poses toxic effects on various tissues, for instance, skin, kidney, 
liver and heart (Goby, 1994 and Morton, et al , 1994). Clinical trials of AS2O3 on 
acute promyelocytic leukemia (APL) also showed that numerous side effects such as 
dry skin, impaired liver function and abnormalities in electrocardiography were 
observed in patients (Shen, et al., 1997，Soignet，et al., 1998，Sun, et al., 1999, 
Ohnishi, et al., 2000 and Unnikrishnan, et al., 2001). Nevertheless, these side effects 
were well tolerated and/or disappeared rapidly with symptomatic treatment. In my 
project，the toxicities of AS2O3 on normal tissues were examined by morphological 
study as well as measurement of the activities of plasma enzymes which are 
originated from different tissues. 
In the in vivo study, the effect of AS2O3 on liver and heart was focused. Since 
HepG2 is a kind of hepatocellular carcinoma, it is essential to ensure that AS2O3 kill 
the tumor cells but not the normal liver cells. On the other hand, numerous anticancer 
drugs like doxorubicin are reported to be cardiotoxic. Thus, AS2O3，which serves as 
an anticancer drug, is important to be clarified whether it is non-cardiotoxic. Hence, 
the effect of AS2O3 on the heart was studied. 
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5.4.1 The Effect of Arsenic Trioxide on Liver 
5.4.1.1 Morphological Study 
Firstly, the effect of AS2O3 on liver was examined by morphological study. 
The schematic diagram (Fig 5.5) showed the typical morphology of normal human 
liver cells and mammals share similar morphology of normal hepatocytes. If there 
were any damages of liver, distorted morphology would be obtained. From my result, 
the morphology of the normal group showed the typical liver cell morphology (Fig 
5.6a). For the negative control and the AS2O3 treated group, there was no change in 
the morphology of cells when compared with the normal group in typical 
experiments (Fig 5.6b and c). This meant that both the negative control and the 
AS2O3 treated groups shared the normal morphology of liver cells. In other words, no 
damage of liver cells was resulted from either saline or AS2O3 administrations. 
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Fig 5.5 The schematic diagram of typical morphology of normal liver cells, (from 




Fig 5.6 Morphological study of liver tissue upon AS2O3 treatment, a) Normal 
group with no tumor inoculation and no drug treatment, b) Negative control group 
with HepG2 cells inoculation and saline injection, c) AS2O3—treated group with 
HepG2 cells inoculation and 5mg/kg AS2O3 injection. The tissue was examined after 
the whole course, namely 3 weeks, of treatment. N represents nucleus, C represnts 
central vein and RBC represent red blood cells. (Hematoxylin and eosin， 
magnification: SOX). 
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5.4.1.2 Enzymatic Study 
The cytotoxicity of AS2O3 toward normal liver tissue was further studied by 
examining the activities of plasma enzymatic markers of liver injury. Aspartate 
transaminase (AST) and alanine transaminase (ALT) were most commonly used in 
the clinic to test liver functions. AST is present in high concentration in cardiac and 
skeletal muscle, liver, kidney and erythrocyte, while ALT is present in high 
concentration in liver, and to a lesser extent, in skeletal muscle, kidney and heart. 
Although liver is not the only site containing AST and ALT, both increases in the 
plasma level of AST and ALT indicate liver damage in a specific manner (Mayne, 
1994). 
From the results, there were no significant differences in the plasma AST (Fig. 
5.7) and ALT level (p > 0.5)(Fig. 5.8) between the normal, the negative control and 
the AS2O3 treated groups. In other words，AS2O3 did not damage the liver. 
5.4.1.3 Brief Conclusion 
From the morphological and enzymatic studies in liver tissues, there were no 
significant differences between the normal, the negative control and the AS2O3 
treated groups. This indicated that AS2O3 at the dosage of 5mg/kg, which is the 
effective dose for killing HepG2 cells in in vivo study, caused no damage to the liver 
of the tumor-bearing host. 
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Fig 5.7 The plasma AST activity upon AS2O3 treatment. The nude mice were 
divided into 3 groups, the normal group with no tumor cell inoculation and no drug 
treatment, the negative control group with HepG2 cells inoculation and saline 
injection and the AS2O3—treated group with HepG2 cells inoculation and 5mg/kg 
AS2O3 injection. Plasma was prepared for measuring the AST activity after the whole 
course, namely 3 weeks, of treatment. 
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Fig 5.8 The plasma ALT activity upon AS2O3 treatment. The nude mice were 
divided into 3 groups, the normal group with no tumor cell inoculation and no drug 
treatment, the negative control group with HepG2 cells inoculation and saline 
injection and the AS2O3—treated group with HepG2 cells inoculation and 5mg/kg 
AS2O3 injection. Plasma was prepared for measuring the ALT activity after the whole 
course, namely 3 weeks, of treatment. 
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5.4.2 The Effect of Arsenic Trioxide on Heart ] 1 
5.4.2.1 Morphological Study 
AS2O3 was reported to affect the beating of the hearts in the clinical trials in 
j 
APL patients (Shen, et al.，1997, Huang, et al., 1998 and Ohnishi, et aL, 2000). 
I However, whether such irregular heart beating poses any lethal effect on the patients 
I needed to be examined. In my in vivo study, the effect of AS2O3 on heart was 
investigated by the morphological study as well as the enzymatic study of the plasma 
markers of heart injury in HepG2-bearing nude mice. These studies may shed some 
light on the probable cytotoxic effect of AS2O3 on the heart. 
Normal cardiac muscles are characterized with tightly packed muscle fibers. 
The results of the typical morphological studies showed that there was no obvious 
change in the packing of muscle fiber in the normal, the negative control as well as 
the AS2O3 treated groups (Fig 5.9). This result suggested that AS2O3 posed no harm 
on the heart. 
tm 
Fig 5.9 Morphological study of heart tissue upon AS2O3 treatment, a) Normal 
group with no tumor inoculation and no drug treatment, b) Negative control group 
with HepG2 cells inoculation and saline injection, c) AsaOs-treated group with 
HepG2 cells inoculation and 5mg/kg AS2O3 injection. The tissue was examined after 
the whole course, namely 3 weeks, of treatment. N represents nucleus. (Hematoxylin 
and eosin, magnification: lOOX). 
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5.4.2.2 Enzymatic Study 
Measurement of the activity of plasma enzymes which are abundant in heart 
was carried out to support the result of the morphological study. For assessment of 
heart damage, lactate dehydrogenase (LDH) and creatine kinase (CK) were used as 
indicators. 
The results showed that the level of the plasma LDH (Fig 5.10) and CK (Fig. 
5.11) were similar between the normal, the negative control and the AS2O3 treated 
groups (p > 0.1). This indicated that no heart damage was resulted from the treatment 
with AS2O3. 
5.4.2.3 Brief Conclusion 
There were no significant differences between the normal, the negative 
control and the AS2O3 treated groups in the morphological study and the enzymatic 
study on the heart tissue. Thus, supporting that AS2O3 at the dosage of 5mg/kg, which 
is the effective dose for killing HepG2 cells in in vivo study, did not damage the heart 
of the tumor-bearing host. 
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Fig 5.10 The plasma LDH activity upon AS2O3 treatment. The nude mice were 
divided into 3 groups, the normal group with no tumor cell inoculation and no drug 
treatment, the negative control group with HepG2 cells inoculation and saline 
injection and the AsaOs-treated group with HepG2 cells inoculation and 5mg/kg 
AS2O3 injection. Plasma was prepared for measuring the LDH activity after the whole 
course, namely 3 weeks, of treatment. 
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Fig 5.11 The plasma CK activity upon AS2O3 treatment. The nude mice were 
i 
divided into 3 groups, the normal group with no tumor cell inoculation and no drug 
treatment, the negative control group with HepG2 cells inoculation and saline 
I j 
injection and the AS2O3—treated group with HepG2 cells inoculation and 5mg/kg 
AS2O3 injection. Plasma was prepared for measuring the CK activity after the whole 
course, namely 3 weeks, of treatment. 
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5.5 Involvement of the Glutathione Redox System 
Several studies suggested that involvement of the glutathione (GSH) redox 
system was one of the action mechanisms of AS2O3 (Dai, et al., 1999, Jing,. et al., 
1999, Yang, et al.，1999 and Bachleitner-Hofmann, et al., 2000). In view of this, the 
participation of GSH redox system was studied by measuring the basal GSH level, as 
well as the activity of glutathione S-transferase (GST) of the liver tissue of the nude 
mice bearing of HepG2 cells after treatment with AS2O3. 
5.5.1 Basal GSH Level 
The change of the basal GSH level of the liver tissue was monitored after the 
whole course of treatment. The result (Fig 5.12) showed that the basal GSH level 
significantly decreased in the negative control group when compared to the normal 
group (p < 0.01). This suggested that the burden of tumor significantly reduced the 
GSH level. On the other hand, the AS2O3 treated group significantly decreased the 
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Fig 5.12 The effect of AS2O3 on the basal GSH level of liver tissue. The nude mice 
were divided into 3 groups, the normal group with no tumor cell inoculation and no 
drug treatment, the negative control group with HepG2 cells inoculation and saline 
injection and the AS2O3—treated group with HepG2 cells inoculation and 5mg/kg 
AS2O3 injection. Homogenate of liver tissues was prepared for measuring the basal 
GSH level after the whole course, namely 3 weeks, of treatment. * p < 0.01. 
i 
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5.5.2 The Activity of Glutathione S-Transferase 
The activity of glutathione S-transferase (GST) of the liver tissue was 
measured. The result (Fig. 5.13) showed that the mean of activity of GST increased 
in the tumor-bearing mice and increased to a larger extent when the mice were 
treated with AS2O3. However, the difference was not statistically significant. 
This result was verified by the in vitro study. The in vitro study showed that 
treatment of HepG2 cells with 2|LIM of AS2O3 for 5 to 7 days increased the cellular 
activity of GST significantly (p < 0.05) (Fig. 5.14). 
5.5.3 Brief Conclusion 
Upon treatment with AS2O3, the basal GSH level of liver tissue decreased 
significantly while the trend of the mean activity of GST was found to be increased 
although the difference between the control and treated group were not statistically 
significant. In vitro study verified that the activity of GST increased upon treatment 
with 2\iM of AS2O3, which is the clinically achievable concentration of AS2O3 in vivo, 
for 5 days or above. These data suggested that GSH redox system is involved upon 
AS2O3 treatment. 
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Fig. 5.13 The effect of AS2O3 on the activity of GST in liver tissue. The nude mice 
were divided into 3 groups, the normal group with no tumor cell inoculation and no 
drug treatment, the negative control group with HepG2 cells inoculation and saline 
injection and the AS2O3—treated group with HepG2 cells inoculation and 5mg/kg 
AS2O3 injection. Cytosolic fraction of liver tissues was prepared for measuring the 
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Fig 5.14 The effect of AS2O3 on the activity of GST by in vitro study. HepG2 cells 
were treated with 2|liM of AS2O3 for 1, 3, 5 and 7 days. The GST activity increased 
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5.6 Summary 
AS2O3 exhibited strong anti-tumor activity. Upon treatment with AS2O3 in 
HepG2-bearing nude mice, the tumor volume and the tumor weight showed a 
I 
I significant reduction when compared with the negative control group. Moreover, it 
！ j 
I did not cause damage to the liver and the heart as shown by the morphological study 
[ 
as well as the measurement of the activities of plasma enzymatic markers of liver and 
heart injuries. In addition, the results showed that GSH redox system may be 
involved in the action of AS2O3 because the basal GSH level in the liver decreased 
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6.1 Introduction 
Multidrug resistant cancer cells may develop upon prolonged treatment with 
anti-cancer drugs. These cancer cells resist to drugs differing in chemical structures 
as well as mechanisms of actions on the cells. Among various multidrug mechanisms, 
overexpression of multidrug transporters, especially P-glycoprotein, is the 
commonest (Stavrovskaya, 2000). The appearance of multidrug resistance poses 
great barrier in the chemotherapy of cancer. As a result, numerous methods are 
developed to alleviate or reverse the multidrug resistance (Di Pietro, et al., 1999, 
Ueda, et al., 1999 and Chan, et al., 2000). In fact, the arising awareness of the use of 
j Chapter 6p.l22 
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I AS2O3 was due to the inhibitory effect of AS2O3 on ATRA-resistant APL cells and on 
I 
. t 
relapsed APL patients. Thus, if AS2O3 is effective in treating other multidrug-resistant 
cancer cells like those overexpressing P-glycoprotein, this will add value to AS2O3 to 
j 
serve as an anti-cancer drug. In view of this, AS2O3 was tested for its ability in 
treating multidrug resistant cancer cells. 
In my project, the multidrug resistant human hepatocellular carcinoma cell 
line, R-HepG2, was used. It is developed by our group as described in Materials and 
Methods. It is characterized with overexpression of mdrl gene and P-glycoprotein 
1 1 1 
• 1 
(Chan, et al., 2000). In this chapter, the effectiveness of AS2O3 on R-HepG2 cells was 
I studied. Firstly, the effect of doxorubicin (DOX), which is a common anti-cancer 
I I drug, on both the parental HepG2 cells and R-HepG2 cells was tested. Then the i 
j I effect of AS2O3 on cell proliferation of R-HepG2 cells was carried out. The action 
i i I I mechanism of AS2O3 on R-HepG2 cells was studied by analysis of cell-cycle phase 
I i i j 
I distribution, DNA fragmentation assay as well as flow cytometry with Annexin V-PI i i 
I 




6.2 The Effect of Doxorubicin on the Parental HepG2 Cells and 
R-HepG2 Cells by MTT Assay 
( 
DOX is a common anti-cancer drug. Moreover, it can be considered as one of 
the most effective anti-cancer drugs. It is prescribed to treat a wide variety of cancers 
such as lung, breast, bladder and liver cancers 
(http://www.cixxo.uk/~cyberville/medizine/doxorubi.htm). In this section, the effect 
of DOX was tested against the parental HepG2 cells and the R-HepG2 cells by MTT 
assay. 
The result showed that the parental HepG2 cells were sensitive to the 
treatment of DOX (Fig 6.1). Although the I C 5 0 of DOX on HepG2 cells for 1-day 
treatment was greater than 20jLiM, it dropped significantly upon further incubation. 
The I C 5 0 of DOX for 3-, 5- and 7-day treatments was 1)liM, 0.5|iM and 0.3 
respectively. 
On the contrary, incubation with 20jLiM of DOX even for 7 days had no effect 
on the cell proliferation of R-HepG2 cells (Fig 6.2). This indicated that R-HepG2 
cells were strongly resistant to DOX. 
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Fig 6.1 The effect of DOX on cell proliferation of HepG2 cells by MTT assay. 
HepG2 cells were treated with various concentrations of DOX and incubated for 1, 3, 
5 and 7 days. The IC50 of DOX on HepG2 cells was >20|uM, 0.5^M and 
0.3|LIM for 1- 3-, 5- and 7-day incubation, respectively. 
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Fig 6.2 The effect of DOX on cell proliferation ofR-HepG2 cells by MTT assay. 
R-HepG2 cells were treated with various concentrations of DOX and incubated for 1, 
3, 5 and 7 days. The IC50 of D O X on R-HepG2 cells was >20|LIM even for 7-day 
treatment. 
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6.3 The Effect of Arsenic Trioxide on Cell Proliferation of 
R-HepG2 Cells by MTT Assay 
R-HepG2 cells were highly resistant to DOX. This result agreed with that of 
the previous study (Chan, et al., 2000). However, whether R-HepG2 cells show the 
I same sensitivity toward AS2O3 remains to be examined. In this section, the effect of 
( •] 
1 AS2O3 on the cell proliferation ofR-HepG2 cells was examined by MTT assay, •j 'i i I The result showed that AS2O3 was effective in inhibiting the cell proliferation 
] 
\ of R-HepG2 cells in a dose- and time-dependent manner (Fig 6.3). The I C 5 0 of AS2O3 
i 
on R-HepG2 cells after 1-day incubation was greater than 20|LIM. However, the I C 5 0 
dropped dramatically to 2.5|iM, l^iM and 0.9jLiM after 3-, 5- and 7-day incubation, 
respectively. Comparing with the parental HepG2 cells, the I C 5 0 of AS2O3 on 
R-HepG2 cells was similar (Table 1). 
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Fig 6.3 The effect of AS2O3 on cell proliferation ofR-HepG2 cells by MTT assay. 
R-HepG2 cells were treated with various concentrations of AS2O3 and incubated for 1, 
3, 5 and 7 days. The IC50 of AssOson R-HepG2 cells was >20\xM, 2.5|LIM, 1|LIM and 
0.9|LIM for 1- 3-, 5- and 7-day incubation, respectively. 
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Table 1 Comparison of the IC50 of AS2O3 between the parental HepG2 cells and 
the R-HepG2 cells. 
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6.4 The Effect of Arsenic Trioxide on Cell-Cycle Phase 
Distribution of R-HepG2 Cells 
From the MTT assay, AS2O3 was shown to be effective in inhibiting the cell 
proliferation of R-HepG2 cells. In this section, the anti-proliferative mechanism of 
AS2O3 on R-HepG2 cells was studied by cell-cycle phase distribution using flow 
cytometry with PI staining. 
Upon treatment with 2jLiM of AS2O3，there was no obvious alternation of each 
cell cycle phase when compared with the control in a typical experiment (Fig. 6.4). 
Nevertheless, the sub-Gl peak became more obvious upon 3-day treatment and the 
percentage of cells in the sub-Gl peak increased to a larger extent when longer 
incubation period was applied. 
In conclusion, AS2O3 inhibited the cell proliferation ofR-HepG2 cells was not 
due to cell-cycle arrest, but due to cytotoxic effect. 
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Fig. 6.4 Results of cell-cycle phase distribution of R-HepG2 cells treated with 
2|xM of AS2O3 for 1, 3, 5 and 7 days by flow cytometry with PI staining. There 
was no obvious alternation of each cell-cycle phase when compared with the control 
and sub-Gl peak became more obvious upon treatment with AS2O3 for 3 days or 
above. 
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6.5 The Underlying Mechanism of the Cytotoxic Effect of Arsenic 
Trioxide on R-HepG2 Cells—Necrosis or Apoptosis? 
From the in vitro study of AS2O3 on HepG2 cells, AS2O3 was shown to exert 
its effect via induction of apoptosis. For treating R-HepG2 cells, both the MTT assay 
and the cell cycle analysis showed that AS2O3 exerted similar cytotoxic effect as that 
on the parental HepG2 cells. Therefore, it is of interest to study whether AS2O3 
mediates its effect via the same mechanism, i.e. induction of apoptosis, when treating 
R-HepG2 cells. In this section, the action mechanism of AS2O3 was studied by DNA 
fragmentation assay as well as flow cytometry with Annexin V-PI staining. 
6.5.1 DNA Fragmentation Assay 
Fig 6.5 showed the result of DNA fragmentation assay of a typical 
experiment. When R-HepG2 cells were treated with 2|LIM of AS2O3，a typical ladder 
pattern was observed upon 5- and 7-day treatments. 
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Fig 6.5 Result of DNA fragmentation assay by AS2O3 treatment. R-HepG2 cells 
were treated with 2[iM of AS2O3 for 1, 3, 5 and 7 days. A ladder pattern was observed 
upon 5- and 7-day treatments. Lane M: 100 base-pair marker; lane 1: control; lane 2: 
1-day treatment; lane 3: 3-day treatment; lane 4: 5-day treatment and lane 5: 7-day 
treatment. 
Chapter 6 p. 
6.5.2 Flow Cytometry with Annexin V-PI Staining 
Induction of apoptosis of R-HepG2 cells upon treatment with AS2O3 was 
ftirther confirmed by flow cytometry with Annexin V-PI staining. 
Fig 6.6 showed the results of a typical experiment. The cell population of the 
control accumulated in the left bottom quadrate. Upon treatment with 2|aM of AS2O3, 
the cell population shifted to the right bottom quadrate. This indicated that apoptosis 
occurred. In addition, the percentage of apoptotic cells increased with increasing the 
incubation time, from 8.1% to 41.5%. This showed that treatment of R-HepG2 cells 
with 2|iM of AS2O3 increased apoptosis in a time-dependent manner. 
6.5.3 Brief Conclusion 
Both DNA fragmentation assay and flow cytometry with Annexin V-PI 
staining showed that AS2O3 exerted its effect on R-HepG2 cells via induction of 
apoptosis. This result was similar to that of the parental HepG2 cells. 
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Fig 6.6 The dot plots with the intensity of PI against that of Annexin V-FITC. 
R-HepG2 cells were treated with 2|LIM of AS2O3 for 1, 3, 5 and 7 days. A shift of cell 
population to the right bottom quadrate was observed upon AS2O3 treatment by flow 
cytometry with Annexin -PI staining. 
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6.6 Examination of the Probable Involvement of Arsenic Trioxide 
as a Substrate of P-Glycoprotein 
From the above study, AS2O3 was found to be effective in inhibiting the cell 
proliferation of R-HepG2 cells via induction of apoptosis. Moreover, the parental 
HepG2 cells and the R-HepG2 cells shared a similar sensitivity toward AS2O3. Thus, 
AS2O3 was probably not the substrate to be bound and pumped out by P-glycoprotein. 
To further examine whether AS2O3 was the target of P-glycoprotein, the maintenance 
of P-glycoprotein expression in R-HepG2 cells by AS2O3 incubation was monitored 
for 4 weeks. 
R-HepG2 cells were incubated with various anti-cancer drugs including 
1.2|aM of DOX, vincristine and AS2O3. The expression of P-glycoprotein in the cells 
was examined on week 1 and 4. The result of Western analysis of a typical 
experiment (Fig. 6.7) showed that the expression of P-glycoprotein began to decrease 
upon 1-week incubation with AS2O3 and nearly disappeared after 4-week incubation. 
On the contrary, the expression of P-glycoprotein of R-HepG2 cells was maintained 
when incubating with DOX and vincristine. This indicated that AS2O3 may not be the 
substrate of P-glycoprotein and so it cannot stimulate and sustain the expression of 
P-glycoprotein in R-HepG2 cells. 
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Fig 6.7 Western analysis of the maintenance of P-glycoprotein upon various 
treatments. R-HepG2 cells were incubated with 1.2|LIM DOX, vincristine and AS2O3 
for 4 weeks and the expression of P-glycoprotein in the cells was examined on week 
1 and 4. HepG2 cells were served as a negative control of P-glycoprotein expression. 
Lane 1: HepG2 cell; lane 2: R-HepG2 cells; lane 3: R-HepG2 cells incubated with 
1.2|LIM of DOX for 1 week; lane 4: R-HepG2 cells incubated with 1.2ILIM of DOX for 
4 weeks; lane 5: R-HepG2 cells incubated with 1.2|iiM of vincristine for 1 week; lane 
6: R-HepG2 cells incubated with L2|iiM of vincristine for 4 weeks; lane 7: R-HepG2 
cells incubated with l.2\iM of AS2O3 for 1 week and lane 8: R-HepG2 cells 
incubated with 1 .2|LIM of AS2O3 for 4 weeks. 
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6.7 Summary 
AS2O3 was effective in inhibiting the cell proliferation of R-HepG2 cells and 
acted through induction of apoptosis. Moreover, R-HepG2 cells shared a similar 
sensitivity to AS2O3 as that of the parental HepG2 cells. In addition, AS2O3 was 
probably not the substrate to be bound and pumped out by P-glycoprotein in 
R-HepG2 cells. 
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Chapter 7 
(Discussion 
7.1 The Significance of the Study of Arsenic Trioxide in the 
Treatment of Liver Cancer 
The medicinal effect of arsenic trioxide (AS2O3) is of great significance, 
though it is also well known for its toxicity. AS2O3 has been used as medicine for 
thousands of years in both the Chinese and Western societies (Gorby, 1994, Shen, et 
al.，1997, Novick，et al., 2000，楊倉良，1991，楊芬明，1992，中醫藥發展籌備委員 
會，1997 and 侯士良，1999). Its use in the cancer treatment was discovered by a 
group of Chinese doctors in 1970s (Merris, 1996). Since then, AS2O3 is found to be an 
effective anti-cancer drug in acute promyelocytic leukemia (APL) as well as non-APL 
leukemia. Recently, studies were carried out to expand the use of AS2O3 in the 
treatment of solid tumors including gastric cancers (Zhang, et al., 1999 and Jiang, 
2001), neuroblastoma (Akao, et al., 1999 and Ora, et al., 2000)，esophageal carcinoma 
(Shen, et al., 2000) as well as head and neck cancers (Seol, et al., 1999). In the present 
study, I have explored the probable use of AS2O3 in the treatment of liver cancer. 
Liver cancer is the second commonest cancer in Hong Kong. The current 
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method in the treatment of liver cancer is surgical resection, radiotherapy as well as 
chemotherapy. However, there are some limitations of each method. Surgical 
resection and radiotherapy are carried out provided that the cancer is restricted to a 
particular region. However, cancer may metastasize to other regions at the later stage 
of cancer development. For chemotherapy, doxorubicin (DOX) and methotrexate are 
more commonly used. However, side effects like toxic hepatitis and heart damage 
may result. Moreover, prolonged treatment with these anti-cancer drugs may give rise 
to multidrug-resistant cancer cells, in turn, poses great obstacle in the cancer therapy 
(http://oncolink.upenn.edu/disease/liver/intro liver.html). Therefore, discovery of new 
drugs for the treatment of liver cancer is essential and important. 
Numerous studies have shown that AS2O3 is effective in treating APL and 
some solid tumors. Moreover there is no detailed report of studying the effect of 
AS2O3 on liver cancer. In view of this, it is of great interest to study the effect of AS2O3 
on treating liver cancer. 
From the present study, both the results of in vitro and in vivo experiments 
showed that AS2O3 was effective in inhibiting the growth of human hepatocellular 
carcinoma cells, HepG2, via apoptotic mechanism. Moreover, it is also effective in 
inducing apoptosis of the multidrug-resistant hepatocellular carcinoma cell line, 
R-HepG2. This may shed some light on the use of AS2O3 in the treatment of liver 








I Before detailed discussion of the use of AS2O3 in the treatment of liver cancer, i j j 
j comparison of my preparation of AS2O3 with others was carried out. Although there •j 
were numerous studies of AS2O3, the preparation of AS2O3 was not the same among •I 
I 
i 1 
] various research groups. Some researchers used the drug which was provided by the 
hospital which may be extracted from Pi'shi and was already applied in the clinical 
trials (Chen, et al” 1996, Chen, et al., 1997 and Jiang, et al., 2000). My AS2O3 sample, 
with purity of 99.0%, was purchased from Sigma Chemical Company. In term of 
i 
！ 
! solution preparation, most researchers prepared it themselves. Some simply used 
water as solvent (Lew, et al., 1999) while some used NaOH (Gianni, et al., 1998 and 
) j Perkins, et al” 2000). Nevertheless, most researchers used PBS to prepare the drug. In 
I I I view of this, I used PBS to prepare the AS2O3 stock which can further be diluted with 
I 1 •； 
j culture media or saline in in vitro and in vivo studies, respectively. 
1 ] 
； However, there was no clear direction in the preparation of AS2O3 from the 
i 
j previous studies, making the experiments difficult to reproduce. In the present study, I 
found that AS2O3 is slightly soluble in cold PBS. Thus, AS2O3 was dissolved in boiled 
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PBS with stirring. Some may wonder whether the heating of AS2O3 would alter the 
properties of AS2O3, in turn, affecting the anti-cancer activity of AS2O3. Or, whether 
AS2O3 would decompose so that the anti-cancer activity was not due to AS2O3, but 




In order to prove that the drug was not affected by the preparation procedures, 
the effect of AS2O3 on the cell proliferation of NB-4 cells as well as brief investigation 
of the action mechanism of AS2O3 on NB-4 cells were carried out. This was because 
NB-4 cell was a typical example of APL cell and was widely used for the study of the 
effect of AS2O3. Thus, comparison can be made between my result and others as the 
targeted cancer cell was the same. 
The cytotoxic effect of AS2O3 on NB-4 cells reported by other workers could 
be reproducible in the present study. From my results, AS2O3 was effective in 
inhibiting the cell proliferation of NB-4 cells in a dose-dependent manner. The I C 5 0 of 
AS2O3 on NB-4 cells upon 1-day incubation was about 2jLiM. Moreover, induction of 
apoptosis of NB-4 cells was found upon treatment with AS2O3 of concentration 
ranging from 0.5-2|aM for 1-day incubation. These results agreed with those of the 
previous studies (Chen, et al., 1996, Chen, et al., 1997 and Wang, et al” 1998)，thus, 
suggesting that there was no problem in my source of AS2O3 and the method of 
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preparation of AS2O3 solution. 
7.3 Effect of Arsenic Trioxide on Human Hepatocellular 
Carcinoma 
The effect of AS2O3 on human hepatocellular carcinoma was investigated by in 
vitro and in vivo studies. For the in vitro experiments, human hepatocellular 
carcinoma cell line, HepG2, was used. The results of in vitro study showed that AS2O3 
was effective in inhibiting the cell proliferation of HepG2 cells in a dose- and 
time-dependent manner. The IC50 of AS2O3 on HepG2 upon 1-, 3-, 5- and 7-day 
treatment was >20|aM, 3.9jLiM, 2.2jLiM and 1.4jLiM, respectively. 
For the in vivo study, nude mice were used as the animal model. Nude mice 
were knockout mice whose immune system was impaired. Thus, any effect on the 
tumor bearing on the mice was due to the drug, but not the inborn immune response 
of the mice. The result of the in vivo study showed that AS2O3 had a strong anti-cancer 
effect because it caused a statistically significant reduction in both the tumor volume 
and the tumor weight. 
In sum, results of both in vitro and in vivo studies showed that AS2O3 was 
effective in inhibiting the growth of human hepatocellular carcinoma, HepG2 cells. 
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7.4 Mechanism Study of Arsenic Trioxide 
i 
For the mechanistic study, the concentration of AS2O3 was fixed to 2|LIM which 
was a clinically achievable concentration. AS2O3 has been used in clinical trials of 
j 
APL for years (Zhang, et al., 1996, Shen, et al., 1997，Sun, et al., 1997，Soignet, et al., 
i 
1998，and Niu, et al., 1999). The dosage for clinical trials was lOmg/day. It was found 
that this dosage was effective in induction of complete remission of both the newly 
diagnosed and relapsed patients. The pharmacokinetic study showed that the steady 
state of plasma arsenic concentration was 0.5-2|LIM (Shen, et al., 1997). In my project, 
therefore, the concentration of AS2O3 for the mechanistic study was fixed to 2jaM in 
order to keep with the in vivo plasma level. 
The action mechanism of AS2O3 was widely studied. It is reported that AS2O3 
exerted its effect by degradation of the fusion protein, PML/RARa in APL cells 
(Chen, et al” 1996, Zhu, et al., 1997 and Shao, et al., 1998), in turn, inducing 
differentiation and triggering apoptosis. This result was supported by that of clinical 
trials (Zhang, et al., 2000). However, some studies showed that AS2O3 mediated its 
effect in a PML/RARa independent manner (Wang, et al., 1998). This suggested that 
the effect of AS2O3 was not restricted to cancers which expressed PML/RARa. 
In fact, apoptosis was shown to be one of the key pathways for AS2O3, 
regardless of the cell types (Chen, et al” 1996, Chen, et al” 1997a, Chen, et al” 1997b, 
j 
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Gianni, et al” 1998，Shao, et al., 1998, Wang, et al., 1998，Dai, et al., 1999，Jing, et al” 
1999，Seol, et al., 1999, Zhang, et al , 1999，Zhu, et al., 1999, Novick, et al , 2000， 
Ora, et al” 2000，Perkins, et al” 2000，Roboz, et al , 2000, Shen, et al., 2000 and Jiang, 
et aL, 2001). Thus, induction of apoptosis of HepG2 cells upon AS2O3 treatment was 
examined. From the analysis of cell-cycle phase distribution, the effect of AS2O3 was 
not due to cell-cycle arrest because there was no obvious alternation of each cell-cycle 
phase when compared with the control. On the contrary, the appearance of the sub-Gl 
peak upon AS2O3 treatment suggested that the effect of AS2O3 was probably due to the 
cytotoxic effect which was resulted from apoptosis. Thus, DNA fragmentation assay 
and flow cytometry with Annexin V-PI staining were carried out to further confirm 
the apoptotic effect of AS2O3. The ladder pattern observed in the DNA fragmentation 
assay as well as the shift of cell population to the right bottom quadrate in the results 
of flow cytometry with Annexin V-PI staining showed that apoptosis took place when 
HepG2 cells were treated with AS2O3. 
To further elucidate the role of AS2O3 in inducing apoptosis, involvement of 
caspase cascade and participation of mitochondria in apoptosis were examined. The 
result of Western analysis showed that caspase-3 was activated upon AS2O3 treatment, 
suggesting the involvement of caspase-3 in AsiOs-induced apoptosis. This finding 
was agreed with that of the previous studies (Akao, et al., 1999, Zhu, et al” 1999, Cai, 
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et al , 2000，and Jiang, et al , 2001). However, did other caspases involve in the 
As203-induced apoptosis? Much more study should be performed, for instance, by 
Western analysis of the caspases like caspase-2 and -8, which are more upstream in 
the caspase cascade (Hengartner, 2000). 
On the other hand, collapse of mitochondrial membrane potential was detected 
upon AS2O3 treatment in some tumor cells (Kroemer, et al” 1999, Zhu, et al., 1999 
and Cai, et al., 2000), in turn, indicating the participation of mitochondria in 
AsiOa-induced apoptosis. In the present study, the involvement of mitochondria in 
AsaOs-induced apoptosis in HepG2 cells was examined by detection of the change of 
mitochondrial membrane potential as well as the release of cytochrome c to the 
cytosol in HepG2 cells. From the result, AS2O3 did not alter the mitochondrial 
membrane potential nor cause the release of cytochrome c to the cytosol, even upon 
7-day treatment. This result suggested that AS2O3—induced apoptosis of HepG2 cells 
was independent of the involvement of mitochondria. This result is contradictory to 
that of the previous studies and may indicate cell-specific action of AS2O3. 
In fact, other pathways may be involved in the action of AS2O3. In the present 
study, the effect of AS2O3 on glucose metabolism was examined. Studies showed that 
cancer cells are often characterized with overexpression of glucose transporters (Gluts) 
(Yamamto, et al., 1990, Younes, et al, 1996 and Au, et al., 1997) so as to cope with the 
Chapter 6 p. Vyj 
increased demand of energy utilization and glucose uptake (Chan, et al., 1983). 
Therefore, interference of Gluts expression (Chan, et al., 1999 and Liong，et al., 1999)， 
glucose uptake and/or glucose metabolism of cancer cells (Bell, et al., 1998) inhibit 
the growth of tumors. The present study showed that AS2O3 exerted no effect on Glut 
expression. However, it inhibited the glucose uptake as well as ATP production in a 
time-dependent manner. 
The expression of Gluts in HepG2 cells was not affected by AS2O3, but the 
glucose uptake was inhibited by AS2O3. This may due to the interference of Glut 
function by AS2O3. Report showed that there were 2 sulfhydryl functional groups 
existed on the plasma membrane surface of the Gluts remote from the glucose binding 
site (Reglinski, 1998). Since AS2O3 has high affinity toward sulfhydryl groups (Gorby, 
1994, Voet, et al , 1995 and Reglinski, 1998), it may change the 3-dimensional 
structure of the Gluts by binding to these sulfhydryl groups and affect the transport of 
glucose into the cells, thus inhibiting the glucose uptake. The ATP production was 
also inhibited upon AS2O3 treatment. This was not due to the impaired function of 
mitochondria because the mitochondrial membrane potential maintained throughout 
the treatment and there was no release of cytochrome c to the cytosol. This indicated 
that mitochondrial function was not disturbed upon AS2O3 treatment. In fact, the 
reduction of ATP production was due to the decrease in the supply of the main 
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metabolite, glucose, for ATP production. In sum, AS2O3 does not affect the expression 
of Gluts but alternates their function, i.e. glucose uptake, in turn, affecting ATP 
production. 
In fact, AS2O3 may affect the glucose metabolism via other pathways, for 
instance, affecting the activity of sulfhydryl-group containing enzymes in the glucose 
metabolism. Pyruvate dehydrogenase is one of the examples (Gorby, 1994，Leibl, et 
al., 1995 and Voet, et al., 1995, http://www.emedicine.com/emerg/topic42.htm). 
Reports showed that trivalent inorganic or organic arsenic inhibits pyruvate 
dehydrogenase by binding to the sulfhydryl groups of dihydrolipoamide. As a 
consequence, conversion of pyruvate to acetyl CoA decreased. In turn, reducing the 
activity of citric acid cycle and hence the production of cellular ATP decreased. 
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) may be another target 
of AS2O3. GADPH is a housekeeping enzyme in glycolysis. However recent studies 
showed that there was an increase in the expression of GADPH in tumors like 
pancreatic adenocarcinoma (Schek, et al., 1988), lung cancers (Tokunaga, et al” 1987), 
cervical cancers (Kim, et al., 1998) as well as hepatocellular carcinoma (Lau, et al , 
2000). The enhanced GADPH level may then contribute to the increased glycolysis. 
Kim (1999) showed that inhibition of the expression of GADPH by antisense 
oligonucleotide reduced the cell proliferation of cervical carcinoma cell lines. Thus, 
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suggesting that GADPH may serve as a target for cancer treatment. On the other hand, 
GADPH has a sulfhydryl group in the active site which is essential for enzyme 
activity (Stryer, 1995). This makes GADPH possible to be a target of AS2O3. Therefore, 
the activity of GADPH may be inhibited when AS2O3 attacks its sulfhydryl group. In 
turn, affecting glucose metabolism as well as ATP production was observed. Thus, 
experiments on assessing the effect of AS2O3 on these sulfhydryl-containing enzymes 
should be carried out in order to elucidate the whole picture of AS2O3 on glucose 
metabolism. 
In fact, glucose- and ATP-deprivation can induce apoptosis (Shim, et al., 1998 
and Bialik, et al., 2000). However, ATP cannot be totally depleted, otherwise necrosis 
occurred. Study showed that ATP depletion more than 50% switched apoptosis to 
necrosis, even under the treatment with well-established apoptosis inducers (Leist, et 
al., 1997). In the present study, glucose uptake was inhibited and hence reduced ATP 
production. The maximum decrease in ATP production occurred upon treatment with 
AS2O3 for 7 days, and the percentage of ATP depletion was about 40%. Thus, it was 
possible that the glucose and ATP depletion triggered apoptosis upon treatment with 
AS2O3 in HepG2 cells. 
Apart from the induction of apoptosis and interference of glucose metabolism, 
involvement of glutathione (GSH) redox system upon AS2O3 treatment in HepG2 cells 
Chapter 6 p. Vyj 
was tested. The results showed that there was a decrease in the basal GSH level but an 
increase in the activity of glutathione S-transferase (GST) upon treatment with AS2O3. 
This suggested that reactive oxygen species (ROS) was involved in the action of 
AS2O3. The decrease in GSH level may be due to the oxidation by ROS and produced 
the reduced form, GSSG. On the other hand, the activity of GST was increased in 
order to remove the ROS from the cells. These results were agreed with previous 
studies which found that the intracellular H2O2 level increased upon treatment with 
AS2O3 (Jing, et al., 1999) or sodium arsenite (Chen, et al., 1998). Jing (1999) 
suggested that the accumulation of H2O2 was due to the inhibition of glutathione 
peroxidase (GPx), a ROS scavenging enzyme, by AS2O3. Moreover, it may be 
possible that AS2O3 increased the mitochondrial production of H2O2. On the other 
hand, Chen (1998) suggested that the increase in H2O2 level was due to the activation 
of NADPH oxidase by sodium arsenite, in turn, increasing the production of 
superoxide. As a consequence, conversion of superoxide to H2O2 resulted and led to 
an increase in intracellular H2O2 level. Then, the increase in H2O2 level induced 
apoptosis. 
In the present study, however, no experiments on investigating the direct 
relationship of AS2O3 and ROS were carried out. Thus, I suggested that production of 
ROS like H2O2 and/or hydroxyl free radicals should be detected upon AS2O3 treatment. 
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Moreover, other enzymes involving in the defense of oxidative-stress such as GPx, 
catalase and sodium dismutase, as well as ROS producing enzymes like NADPH 
oxidase should be studied. 
In conclusion, AS2O3 recruits a number of pathways in order to exert its 
anti-proliferative effect in treating cancers. The action mechanisms include induction 
of apoptosis independent of the participation of mitochondria, interference of glucose 
metabolism by reducing the function of Gluts, as well as involvement of GSH redox 
system possibly by producing ROS and inactivating some enzymes in oxidative-stress 
defense system. However the interaction between these pathways is not clear. 
Nevertheless apoptosis is believed to be the final consequence of the action of AS2O3. 
Further investigation should be carried out to elucidate the whole picture of the action 
mechanism of AS2O3. A proposed mechanism of AS2O3 was shown in Fig. 7.1. 
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Fig. 7.1 A proposed mechanism of AS2O3. Words in purple were the result or 
implications found in the present study, crosses represent no effect and question marks 
represent unknown. AS2O3 exerted the anti-proliferative effect via induction of 
apoptosis with caspase-3 activation but independent of the participation of 
mitochondria. Moreover, AS2O3 interfered the functions of gluts, in turn, inhibiting the 
glucose uptake and ATP production. GSH redox system may also be involved in the 
action of AS2O3 as AS2O3 reduced the basal GSH level and increased the GST activity. 
I I 
There are still many unknowns in the whole picture of the action mechanism of AS2O3 
Nevertheless apoptosis is believed to be the final consequence of the action of AS2O3. 
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7.5 Dosage of Arsenic Trioxide Used in In Vivo Study 
For the in vivo study, the dosage of AS2O3 was 5mg/kg in HepG2-bearing nude 
mice. Compared to the effective treatment doses in human (Zhang, et al., 1996, Shen, 
et a l , 1997, Soignet, et al , 1998, Niu, et al., 1999，Sun, et al., 1999, Camacho, et al., 
2000，Zhong, et al., 2000 and 孫鴻德，1992), relatively high dose of AS2O3 was 
needed to achieve tumor growth inhibition in the nude mice model. This was in 
agreement with previous animal studies which showed that mice required higher 
doses than human to obtain similar plasma level of anti-tumor drugs 
(Lallemand-Breitenbach, et al., 1999 and Ora，et al., 2000). 
The availability of effective AS2O3 in blood circulation is affected by the 
metabolism of arsenic. Studies showed that inorganic trivalent arsenic compounds 
were methylated in the liver and mono- and/or diemethylarsenic acid (MMA and 
DMA, respectively) were produced for excretion (Tarn, et al., 1979，Vahter, 1981， 
Vahter，et al., 1983 and Styblo, et al., 1999). Styblo (1999) also showed that rat 
exhibited a higher rates of methylation of inorganic arsenic compounds when 
comparing with human. Therefore, this suggested that the clearance of AS2O3 in the 
blood circulation of mice was higher than that of human. Hence, a higher dose of 
AS2O3 was required to achieve a similar plasma concentration so that it can exert 
effective cancer treatment in mice. 
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7.6 Cytotoxicity of Arsenic Trioxide toward Normal Tissues 
AS2O3 exhibited strong anti-tumor activity. However, side effects were often 
observed in the clinical trials of leukemia patients. The side effects included dry skin, 
impaired liver function and abnormalities in electrocardiography (Shen, et al , 1997， 
Soignet, et al., 1998, Sun, et al., 1999, Ohnishi, et al., 2000 and Unnikrishnan, et al., 
2001). Nevertheless, these side effects were well tolerated and/or disappeared rapidly 
with symptomatic treatment. In the present project, the cytotoxic effect of AS2O3 
toward normal tissue was evaluated by morphological study as well as measurement 
of the activities of plasma enzymatic markers of liver and heart injuries. The results 
showed that there was no significant difference between the normal, the negative 
control and the AS2O3 treated groups. This suggested that AS2O3 at the dosage of 
5mg/kg did not damage the liver and the heart in the animal study. This may imply 
that AS2O3 was not toxic toward normal tissues if the concentration applied in cancer 
treatment was well controlled. 
Another factor contributed to the low/no toxicity of AS2O3 toward normal 
tissues was the route of administration. Reports showed that oral administration of 
AS2O3 was associated with severe gastrointestinal and liver side effects (Chen, et al., 
1997，Shen, et al , 1997 and Ora, et al., 2000). Thus, AS2O3 was introduced to the 
patients, or in our case, to the mice, via intravenous administration. 
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In sum, AS2O3 was not toxic toward normal tissues in nude mice if the 
concentration used in cancer treatment was well controlled and was introduced to the 
body via intravenous administration. 
7,7 Effect of Arsenic Trioxide on Multidrug-Resistant Human 
Hepatocellular Carcinoma Cell Line, R-HepG2 
Multidrug resistant cancer cells may develop upon prolonged treatment with 
anti-cancer drugs. These cancer cells resist to drugs differing in chemical structures as 
well as mechanisms of action on the cells. Among various multidrug resistant 
mechanisms, overexpression of multidrug transporters, especially P-glycoprotein, is 
the commonest (Stavrovskaya, 2000). The appearance of multidrug resistance poses 
great obstacle in the chemotherapy of cancer. As a result, numerous methods are 
developed to alleviate or reverse the multidrug resistance (Di Pietro, et al , 1999， 
Ueda, et al., 1999 and Chan, et al., 2000). In fact, the arising awareness of the use of 
AS2O3 was due to the inhibitory effect of AS2O3 on ATRA-resistant APL cells and on 
relapsed APL patients. Thus, if AS2O3 is effective in treating other multidrug-resistant 
cancer cells like those overexpressing P-glycoprotein, this will add value to AS2O3 to 
serve as an anti-cancer drug. In view of this, AS2O3 was tested for its ability in treating 
multidrug resistant hepatocellular carcinoma cell line, R-HepG2, which was 
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characterized with upregulation of mdrl gene and overexpression of P-glycoprotein 
(Chan, et al., 2000). 
The results showed that AS2O3 was effective in inhibiting the cell proliferation 
of R-HepG2 cells in a dose- and time-dependent manner and acted through induction 
of apoptosis. Moreover, R-HepG2 cells acquired similar sensitivity toward AS2O3 as 
that of the parental HepG2 cells. This suggested that AS2O3 was not a target of 
P-glycoprotein. This finding is of great clinical significance because this can help 
explore the potential use of AS2O3 in treating patients with multidrug-resistance. In 
order to further examine whether AS2O3 was the target to be bound and pumped out by 
P-glycoprotein in R-HepG2 cells, the maintenance of P-glycoprotein expression in 
those cells was monitored for 4 weeks upon treatment with AS2O3 and other 
anti-cancer drugs including doxorubicin (DOX) and vincristine. This was due to the 
reason that expression of P-glycoprotein in multidrug resistant cells can be stimulated 
and sustained by its substrate (Budworth, et al., 1997). The result showed that the 
expression of P-glycoprotein of R-HepG2 cells began to drop upon treatment with 
AS2O3 for 1 week and nearly disappeared after 4-week incubation. On the contrary, the 
expression of P-glycoprotein was maintained when R-HepG2 cells were incubated 
with DOX and vincristine. This may indicate that AS2O3 is not the target of 
P-glycoprotein and so it cannot stimulate and sustain the expression of P-glycoprotein. 
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In fact, this was indirect and preliminary data showing that AS2O3 was not a substrate 
of P-glycoprotein. To examine whether AS2O3 was the substrate of p-glycoprotein, 
more direct methods should be done, for instance, monitoring the exclusion and/or 
accumulation of AS2O3 in R-HepG2 cells by using radiolabelled isoptope. Moreover, 
much effort has to be paid in understanding the mechanism of AS2O3 to escape from 
P-glycoprotein. 
7.8 Conclusions and Future Prospect 
From the present study, results of both in vitro and in vivo experiments showed 
that AS2O3 was effective in inhibiting the growth of human hepatocellular carcinoma, 
HepG2 cells. 
The action mechanism of AS2O3 was complicated. It acts through induction of 
apoptosis but independent of the participation of mitochondria. Moreover, it interferes 
with the function of Gluts and so it inhibited glucose uptake as well as ATP 
production. In addition, GSH redox system was found to be involved because AS2O3 
may produce ROS and/or inactivate some enzymes in oxidative-stress defense system. 
Nevertheless, the relationship and sequence between these pathways are not fully 
understood. Further investigation should be carried out to elucidate the whole picture 
of the action mechanism of AS2O3. In turn, this work will help improve and modify 
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the therapeutic protocol of AS2O3 in cancer treatment. 
The present study also showed that AS2O3 was effective in inhibiting the 
growth of multidmg-resistant human hepatocellular carcinoma, R-HepG2, via 
induction of apoptosis. In fact, it is of clinical significance to test whether AS2O3 was 
effective in the treatment of other multidrug resistant tumor cells. This may help 
explore the use of AS2O3 in treating multidmg-resistant patients. 
In order to use AS2O3 in cancer treatment, study of the pharmacokinetic 
properties and dosing schedules of AS2O3 should be further investigated. Moreover, 
combined treatment with other conventional anti-cancer drugs should be carried out. 
This can help extend the use and activity of AS2O3 in cancer therapy. 
In sum, AS2O3 was found to be an effective anti-cancer drug in the present 
study. However, its use in cancer treatment is still controversial because of its 
potential toxicity toward normal tissues. Thus, to fully utilize AS2O3 in cancer therapy, 
much more efforts should be paid on the study of its action mechanism, 
pharmacokinetic properties, dosing schedules as well as potential hazards. 
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